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 1 
Riassunto 
 
Le cellule staminali emopoietiche sono le cellule responsabili della produzione degli 
elementi maturi del sangue midollare; la pancitopenia e’ una condizione che 
caratterizza la presentazione clinica di diverse patologie, sia ematologiche che 
extra-ematologiche, dove viene intaccata la funzionalita’ midollare. Le sindromi da 
insufficienza midollare di origine primaria (BMF) sono un gruppo eterogeneo di 
patologie caratterizzate da un disordine immunologico in grado di determinare la 
distruzione delle cellule staminali emopoietiche con una conseguente globale o 
selettiva aplasia midollare. In particolare, la distruzione su base autoimmunitaria 
delle cellule staminali e’ alla base delle AA. Gli stessi meccanismi patogenetici 
sono coinvolti in emopatie clonali quali l’emoglobinuria parossistica nottura (PNH) 
ed alcuni tipi di sindromi mielodisplastiche (MDS). Nelle MDS, sono stati ipotizzati 
diversi meccanismi immunologici in grado di determinare la comparsa della 
citopenia: a) l’attacco immunologico alle cellule staminali potrebbe essere parte 
integrante delle sorveglianza anti-tumorale in risposta alle cellule displastiche 
midollari ed, in tal caso, essere non sufficientemente specifico tale da dare origine, 
come danno collaterale, ad inibizione della normale attivita’ emopoietica; b) 
l’attacco immunologico potrebbe essere diretto contro le cellule staminali normali, 
come si verifica nell’AA, favorendo l’ “escape” di cloni ematopoietici mutati. Questo 
ultimo meccanismo e’ stato chiamato in causa per spiegare la patogenesi della 
PNH. In ogni caso numerosi dati indicano che il sistema immunitario ha un ruolo 
centrale nella fisiopatologia delle sindromi da insufficienza midollare; in questo 
studio abbiamo cercato di identificare dei fattori, geneticamente determinanti, che in 
qualche modo possano condizionare il funzionamento del sistema immunitario ed, 
in seconda battuta, lo sviluppo di una disfunzione midollare. La nostra ipotesi si e’ 
basata sull’idea che gli antigeni leucocitari umani (HLA), i recettori inibitori delle 
cellule NK (KIR) cosi’ come la risposta citochinica associata alle varianti genetiche 
delle citochine e dei loro recettori e promotori, possano influenzare la risposta 
immune e predisporre ad una risposta immunitaria aberrante. Tali reazioni 
potrebbero essere responsabili dei meccanismi patogenetici delle sindromi da 
insufficienza midollare di origine immuno-mediata. Per tale motivo siamo andati ad 
analizzare l’associazione tra BMF e numerosi fattori immunogenetici in 167 
pazienti, includendo fattori quali l’antigene leucocitario umano (HLA), il genotipo dei 
recettori per NK immunoglobulin-like (KIR), I KIR/KIR-L mismatch, ed i polimorfismi 
di singoli nucleotidi per i geni del CTLA-4 (+49 A/G), CD16(!158V/F), e di alcune 
citochine quali: IL-1" (-889 T/C), IL-1R (-1970 C/T), IL-1RA (11100 T/C), IL-4RA (+ 
190 G/A), IL-1# (-511 C/T, +3962 T/C), IL-6 (-174 C/G, nt565 G/A), IL-10 (-1082 
G/A, –819 C/T, -592 C/A), IL-12 (-1188 C/A), TGF-# (codon 10 C/T, codon 25 G/C), 
TGF-#R2 (+358 A), INF-$ (+874 A/T), TNF-" (-308 G/A, –238 G/A), IL2 (-330 T/G, 
+166 (G/T), IL4 (-1098 T/G, -590 T/C, -33 T/C).  Il nostro studio porta alla 
conclusione che la regolazione genetica dell’infiammazione e il pathway 
immunologico T-cell mediato possono essere coinvolti nella patogenesi delle 
sindromi da insufficienza midollare, rafforzando l’ipotesi che sia l’ AA che la PNH 
sono disordini autoimmunitari organo-specifici.  
 
 
 
 2 
SUMMARY 
 
Hematopietic stem cells (HSC) are responsible for the production of mature blood 
cells in bone marrow; peripheral pancytopenia may result from several different 
conditions, including hematological or extra-hematological diseases (mostly 
cancers) affecting the marrow function as well as primary failure of hematopoiesis. 
Although the clinical presentation may appear homogeneous, primary bone marrow 
failure syndromes are a heterogeneous group of diseases with specific pathogenic 
mechanisms, which share a profound impairment of the hematopoietic stem cell 
pool resulting in selective or global marrow aplasia. Immunomediated elimination of 
stem cells due to the presence of a cross-reactive antigen or autoantigen restricted 
to the stem cell compartment may be responsible for AA. Similar pathophysiologic 
mechanisms may also operate in related diseases such as paroxysmal nocturnal 
hemoglobinuria (PNH) or some forms of myelodisplastic syndromes (MDS). Most 
often these disease are characterized by an extrinsic damage of hematopoietic 
stem cells that affect their function. Effector mechanisms in hematopoietic inhibition 
may involve various pathways, including release of cytokine leading to apoptosis of 
hematopoietic progenitor and stem cells. In MDS, various possible mechanisms 
have been postulated to explain the occurrence of cytopenia due to inhibition of 
normal residual hematopoiesis. For example, the immune attack can be part of 
physiologic anti-tumor surveillance response to abnormal and/or dysplastic cells in 
the bone marrow. In such situation, the immune attack may be sufficiently specific 
and results in collateral damage with inhibition of normal hematopoiesis. 
Conversely, the initial immune attack may be directed against normal stem cells as 
in AA, resulting in selection pressure with outgrowth and escape of mutant 
hematopietic clones. Similar consideration apply to the evolution of 
glycophosphatidyl- deficient clones in PNH. A number of evidences demonstrated 
that the immune system plays a pivotal role in the pathophysiology of bone marrow 
failure syndromes. In this study we planned to look for biological factors, especially 
at the genetic levels, which may somehow drive the function of the immune system, 
possibly leading to the development of a form of bone marrow failure. Our 
hypothesis is that the human leukocyte antigen (HLA) and killer inhibitory receptor 
(KIR) background as well as the quality of the cytokine response due to genetic 
variants of the cytokine, cytokine receptors genes and their promoters may 
modulate the quality of immune response and predispose to aberrant overshooting 
immune reactions. Such reactions may determine the risk for immune-mediated 
bone marrow failure. The association of BMF with a number of immunogenetic 
factors was analysed in 167 patients, including human leucocyte antigen (HLA) and 
killer-cell immunoglobulin-like receptor (KIR) genotype, KIR/KIR-L mismatch, CTLA-
4 (+49 A/G),CD16!158V/F, and cytokine single nucleotide polymorphisms 
including: IL-1" (-889 T/C), IL-1R (-1970 C/T), IL-1RA (11100 T/C), IL-4RA (+ 190 
G/A), IL-1# (-511 C/T, +3962 T/C), IL-6 (-174 C/G, nt565 G/A), IL-10 (-1082 G/A, –
819 C/T, -592 C/A), IL-12 (-1188 C/A), TGF-# (codon 10 C/T, codon 25 G/C), TGF-
#R2 (+358 A), INF-$ (+874 A/T), TNF-" (-308 G/A, –238 G/A), IL2 (-330 T/G, +166 
(G/T), IL4 (-1098 T/G, -590 T/C, -33 T/C). Our data suggest that genetic regulation 
of inflammatory and T-cell-mediated immunological pathways could be involved in 
the pathgenesis of bone marrow failure, reinforcing the view that both AA and PNH 
are organ-specific autoimmune disorders. 
 
 
 3 
Introduction 
 
 
Hematopoietic stem cells (HSC) are responsible for the long-life production 
of mature blood cells; they physiologically work within the bone, where they interact 
with other cellular types and soluble factors, formally known as microenvironment, 
to constitute the bone marrow [1]. Hematopoiesis is a hierarchical process which 
starts from the multipotent HSC and proceeds through more committed and 
differentiated progenitors [2]; while differentiation and maturation are essential for 
producing mature circulating cells, self-renewal is the main feature of HSC ensuring 
the long-term maintenance of hematopoiesis [3]. All these functions are finely 
regulated by a complex network which includes cell-cell interactions between 
hematopoietic and stromal cells, as well as the action of several soluble cytokines, 
often working in a paracrine fashion within the so-called hematopoietic niches. 
Bone marrow is a functional tissue which may be insufficiently performing in several 
conditions, all clinically presenting as mono- or multi-lineage cytopenia. Bone 
marrow failure (BMF) may result from various extra-hematological diseases, such 
as malignancies, infectious diseases and nutritional deficiencies, all of them 
secondarily affecting the HSC function. Similarly, hematopoiesis may be impaired in 
various hematological diseases, such as lymphoproliferative and myeloproliferative 
disorders; even when the disease affects the HSC itself, such as in leukemias, the 
BMF is usually considered secondary to the underlying disease. By contrast, 
primary BMF syndromes are a heterogeneous group of hematological diseases 
(Tab. 1) characterized by the absence of any other disorder potentially affecting 
marrow function. However, while they are considered distinct disease, in some 
cases their patophysiology involves similar pathogenic mechanisms, which finally 
lead to stem cell and/or hematopoietic progenitor damage. In this work, we test the 
hypotesis that genetic factors may affect the functioning of the immune system, and 
especially the complex cytokine network which may interfere with normal 
hematopoiesis. 
 
APLASTIC ANEMIA 
 
Aplastic anemia (AA) is the paradigm of bone marrow insufficiency; as other BMF 
syndromes, it is characterized by peripheral pancytopenia [4]. The hallmark of AA is 
an empty or fatty marrow as evidenced by bone aspirate and biopsy, which directly 
demonstrates the contraction of the hematopoietic cell compartment leading to 
deficient hematopoiesis. According to the hierarchical model of hematopoiesis, the 
desert marrow in AA results from the impaired HSCs function. The alteration 
affecting the HSC may be different depending on the specific form of AA; indeed, 
even within the AA setting, different entities may be sorted, each one with specific 
pathophysiologic mechanisms. A first distinction has to be made between 
constitutional and acquired forms of AA. In the present thesis, we will not deal with 
constitutional forms. 
 
 
Acquired aplastic anemia. Acquired forms of AA are far more frequent than the 
constitutional ones; typically they affect young adults or elderly people, who present 
with peripheral pancytopenia in absence of other hematological diseases. 
Pancytopenia of AA patients results from the impairment of the hematopoietic 
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progenitor compartment, including HSC and more committed progenitors; the 
nature of the injury damaging hematopoiesis very often remains undetected (Fig. 
1). Cytotoxic drugs and radiation are the best examples of a direct injury to HSC; 
although stem cells, due to their dormant nature, are more resistant to cytotoxic 
drugs, for most agents a dose-response relationship with the degree of stem cell 
damage can be established. However, iatrogenic direct injury by chemotherapy or 
radiation is rarely involved in marrow failure syndromes; sometimes, although 
exposure to a list of drugs may be documented (Tab. 1), a definitive causative 
relationship cannot be demonstrated. Indeed, even if a putative inciting agent 
directly attacks the stem cell pool, causing a permanent depletion of HSC, the 
clinical presentation of cytopenia may be delayed for weeks or months, appearing 
just when a critically low stem cell number is reached. These considerations are 
applicable to chemical agents as well as to a number of viruses which may infect 
hematopoietic progenitors; in all these conditions the damaging mechanism may 
also involve non-direct injury of the HSC. The indirect damage of HSC is mainly 
sustained by immune effector mechanisms (Fig. 1), which may be possibly 
triggered by viruses or by drug metabolites. An appropriate example for such a 
mechanism is the hepatitis/AA syndrome, in which AA follows with a delay of 
months an episode of acute hepatitis that carries all the characteristics of a viral 
infection. The viral agent responsible for this syndrome has not been identified; it is 
possible that at the time of overt cytopenia the viral infection is already cleared, AA 
being mediated by lymphocytes recognizing a cross-reactive antigen in the marrow. 
EBV-associated AA has been described; even this form seems not to be mediated 
by direct viral cytoxicity, rather by the immune system.  Similar pathogenic 
mechanisms may be postulated in the majority of cases of idiopathic AA, possibly 
involving the presence of neo-antigens or cross-reactive triggering antigens which 
result in a breach of immune tolerance; this would generate an immune-mediated 
attack towards hematopoietic progenitors, leading to HSC consumption or 
functional impairment with subsequent pancytopenia. 
Regardless the nature of injury, AA patients are characterized by a severe 
dysfunction of the hematopoietic stem cells; this defect has been deeply 
characterized on both quantitative and qualitative fashion. As those with 
constitutional AA, patients with acquired AA show a very low number of 
hematopoietic progenitors, as measured by flow cytometric CD34+ cell assessment 
or by in vitro colony assays [5-7].  By flow cytometry, CD34+ cells are reduced in all 
AA patients, and the contraction affects both committed and immature CD34+/c-kit- 
or CD34+CD38- progenitors [8].  Unlike in murine models, the measurement of 
more immature progenitor and stem cells is not easily accomplished in humans.  
Consequently, several surrogate in vitro stem cell assays have been developed, 
including long-term culture-initiating cells (LTC-IC) as well as cobblestone forming 
assay [9,10].  The LTC-IC assay assesses cells capable of colony formation after 5 
weeks in long-term bone marrow culture; LTC-ICs share the frequency, phenotype, 
and kinetic properties of true stem cells [10-12]. Several studies indicate a profound 
deficiency in LTC-IC as well as cobblestone unit initiating cells in all patients with 
AA [5,9,13]. At the time of clinical presentation, the number of LTC-IC is usually at 
least one log below the normal level; combined with a reduction in total marrow 
cellularity to <10%, the stem cell number in AA is estimated to be reduced of at 
least two logs compared to healthy individuals [9].  Neither the LTC-IC number nor 
that of colony forming cells correlate with the blood counts, suggesting that in 
addition to the quantitative defect, a functional impairment may be present [5]; this 
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may also be extrapolated by the observation that the clonogenic capacity of an 
individual progenitor is lower than in normals. The reduced clonogenicity was 
demonstrated both on CD34+ cells (as number of colonies obtained from a purified 
CD34+ population) and on the putative stem cell LTC-IC (as number of secondary 
colonies assayed from LTC-IC in limiting dilution experiments) [5,9,14].  These 
findings suggest that the hematopoietic stem cell compartment is affected by the 
pathophysiologic process operating in AA, whereas mesenchymal or even more 
immature pluripotent stem cells are likely functionally normal.  Indeed, several 
studies have documented that marrow cells from AA patients are able to generate 
in vitro perfectly functional stromal layers, as confirmed on cross-over experiments, 
which strongly support that stromal progenitors or early pluripotent stem cells are 
not affected in AA [15-17]. This is also confirmed by the clinical observation that 
allogeneic stem cell transplantation is a highly successful therapy for AA, even if 
most stromal elements remain of host origin. Serial studies were conducted to 
determine the number of stem cells during the course of the disease and the 
kinetics of decline/recovery in stem cell number; a profound defect in LTC-IC 
number may persist for a long time, even in patients successfully treated by 
immunosuppression [9,13].  In most cases, a residual numerical LTC-IC defect may 
be permanent, despite blood counts full recovery, while a complete reconstitution is 
found only in a minority of patients with sustained complete remission [9]. 
Nevertheless, at least a partial recovery of stem cells is possible, and a highly 
contracted stem cell pool can sustain a seemingly normal blood cell production, 
even if the compensatory capacity in response to stress conditions may be 
diminished.  
A qualitative defect of HSC is suggested by the reduced clonogenic potential, as 
already mentioned above [5]; however, this does not necessarily imply that the 
dysfunction is intrinsic to the HSC as in constitutional AA. Clearly, the 
hematopoietic recovery following successful immunosuppression demonstrates that 
some stem cells must have been spared from the pathologic process; impaired 
primary and secondary clonogenic capacity concerns a majority of HSCs, which 
likely are most damaged, but not all individual HSCs. Indeed, it is well known that 
CD34+ cells from AA patients show a high proportion of apoptotic cells [18-20]; it is 
possible that a few HSC resisting to the apoptotic stimuli in vivo may have normal 
functional properties. Several decades of laboratory experiments have suggested 
that the nature of the stem cell damage in AA involves activation of general immune 
effector mechanisms (Fig. 1) [21-23]. The stem cell damage can be due to direct 
cell-mediated killing by cytotoxic lymphocytes (CTL) as well as by cytokine-
transduced inhibition; the latter is documented by excess production of type I 
cytokines, especially interferon-$ and tumor necrosis factor-" [24-26]. Additionally, 
Fas-ligand or tumor necrosis factor-derived inhibitory ligand (TRAIL) appear to play 
an important role as effector cytokines in the hematopoietic inhibition in AA 
[18,24,25,27]. Such mechanisms may not be restricted to the primary target only, 
but may also attack innocent bystander cells; ultimately, these factors result in 
apoptosis of all existing cells. Fas, IFN-! and TNF-" modulate the expression of 
their receptors through feedback mechanisms; in this way they may enhance each 
other action [26,28]. Furthermore, the effects of individual factors may be additive 
or synergistic [28];  chronic exposure to these cytokines in vivo may be more 
damaging compared with in vitro models, which challenge the acute effects of high 
cytokine concentrations [62]. Apoptosis is the main key mechanism of HSC 
damage. The apoptotic machinery may be constitutively activated in differentiated 
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cells, which may need appropriate signals to survive; in contrast, in stem cells 
apoptosis likely has to be induced by specific stimuli. Indeed, the abundance of 
trophic signals argues against the lack of survival signals (e.g. growth factors) as a 
mechanism of apoptosis for HSCs [30]. Increased apoptotic rate within the CD34+ 
cell population from AA patients has been demonstrated [18-20]; in addition, CD34+ 
cells from AA show increased expression of Fas [19,20,28,31], which may be 
induced by IFN-! and TNF-" in an aplastic marrow [18,25,32,33].  Both cytokines 
can up-modulate Fas expression even in normal CD34+ cells [28,34]; CD34+ cells 
derived from AA patients appear to undergo apoptosis in response to Fas at a 
higher rate compared with normal CD34+ cells [19,20,27,31].   Additional pathways 
of apoptosis may involve nitric oxide or oxygen radical secretion, similarly to what 
observed in FA; the production of such factors in hematopoietic progenitors may be 
triggered by classical pro-apoptotic stimuli, such as inhibitory cytokines, leading to 
apoptosis in a paracrine fashion [35,36].  
A more accurate description of HSC in AA has become possible with the 
oligonucleotide microarray technology, which allows quantitation of the expression 
levels of a large number of genes. Recently, the gene expression profile in healthy 
human CD34+ stem/progenitor cells has been reported; the same technology has 
been applied to assess gene expression in CD34+ marrow cells from AA patients 
[37]. The study documented that the expression of several genes implicated in 
apoptosis and cell death was markedly increased in AA CD34+ cells, as well as that 
of genes involved in the negative control of cell proliferation. Examples of up-
regulated genes were the death receptors Fas, DR3, DR5, TNFRII, and TRAIL. In 
contrast, genes promoting cell cycle progress showed a lower expression compared 
to CD34+ cells from healthy individuals, possibly explaining the inability of the 
residual stem cells to compensate the progenitor pool contraction. As anticipated 
from other evidences of heightened immune activity, several cytokine/chemokine 
signal transducer genes, stress response genes, and defense/immune response 
genes were up-regulated. In summary, the transcriptome analysis of HSC in AA is 
consistent with the presence of stressed, dying and immunologically activated 
target cells rather than of an intrinsically abnormal population. This support the 
hypothesis of an organ-specific immune attack on hematopoietic stem/progenitor 
cells, possibly T-cell mediated.  
The presence in the circulation and in marrow of activated cytotoxic lymphocytes 
(CTLs), which inhibit hematopoiesis in vitro, has been reported in AA patients 
[38,39];  furthermore, we and others have described abnormalities of T cells and of 
the TCR repertoire [40-43], suggestive of an oligoclonal T cell response.  For some 
patients, CD4+ and CD8+ T cell clones which responded to and destroyed 
autologous hematopoietic progenitors were characterized after in vitro 
immortalization [38,43].  More recently, we have identified dominant T cell 
clonotypes by sequencing the CDR3 of the TCR-# chain [44]; cells bearing this 
clonotype were found expanded in vivo, likely as a result of an antigen-driven 
dominant immune response, suggesting their pivotal pathophysiologic role. Indeed, 
these pathogenic T cell clones appeared to correlate with disease activity, and 
showed potent cytotoxicity directed against autologous marrow progenitor cells. 
The observed homology among various patient-specific clonotypes may suggest a 
semi-public immune response against common epitopes; however, the antigen(s) 
driving the immune attack on the HSC are still unknown, as well as the possible 
primary abnormalities of HSC leading to the breach of immune self-tolerance [44].  
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Other qualitative abnormalities of HSCs and their progeny in AA have been 
described; the most worthy is increased telomere shortening. In true stem cells, 
self-renewal does not result in telomere shortening, due to the activity of 
telomerase [45-47]; however, telomerase activity decreases upon commitment and 
differentiation [48], thus telomere length of the progeny reflects the number of 
doublings of the committed and more mature progenitors.  Short telomeres have 
been reported in constitutional AA, as mentioned; even patients affected by 
acquired AA show telomere shortening, as measured by various methods 
[47,49,50].  Apparently paradoxically, patients with chronic moderate AA showed 
telomeres shorter than those of patients with a more severe disease; actually, in 
acute severe cytopenia, telomere shortening may not be evident due to a more 
extended block of stem cell cycling [47,49,50]. Upon recovery, due to recruitment of 
new stem cells, telomeres of the progeny may provide longer measurements again; 
however, if the stem cell number operating at a given time is small, in order to 
maintain a normal circulating cell number more divisions are needed and telomere 
shortening may be more pronounced.  Proper function of the telomerase complex 
requires the presence of an intact RNA primer (TERC), as well as of the functional 
protein (TERT). DKC, a mutation in the TERC gene has been occasionally reported 
in patients with acquired AA, harboring very short telomeres; however, this defect 
seems restricted to patients with positive family history, and to peculiar clinic 
presentation (early onset, chronicity, lack of response to immunosuppression). 
Thus, these cases likely represent uncommon presentation of a form of 
constitutional aplasia. More recently, AA patients with a mutation within the TERT 
gene have been described. As patients with TERC mutation do, subjects with 
abnormal TERT show increased telomere shortening and low telomerase activity; 
this suggests that heterozygous mutations in the TERT gene impair telomerase 
activity by haploinsufficiency, and may be risk factors for marrow failure, possibly 
explaining some cases of familial acquired AA. On the other side, telomere 
shortening evidenced in typical acquired forms of AA is likely to be considered an 
epiphenomenon linked to the proliferative stress of surviving progenitors rather than 
the expression of primary lesions of the HSC, as for DKC. Of note, once a critical 
telomere length is reached, chromosomes may become unstable; such a 
mechanism could be one of the explanations for the possible clonal evolution from 
AA into myelodysplasia [51,52] or even acute leukemia. The acquisition of stem cell 
damage and the expansion of the dysplastic clone may be the result of a clonal 
escape; an alternative explanation is that the depletion of normal stem cells may 
facilitate the recruitment of a preexisting defective (under normal circumstances 
quiescent) stem cell (oligoclonality theory). A different susceptibility to the depletion 
mechanisms between normal and possible mutated stem cells has also been 
hypothesized. Finally, it has been hypothesized that exogenous G-CSF may 
interfere with some of these processes [53,54].  
 
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 
 
Paroxysmal nocturnal hemoglobinuria (PNH) is a marrow failure syndrome 
closely embedded with AA; PNH is a clonal stem cell disorder arising by an 
acquired somatic mutation in the phosphatidylinositol glycan class A (PIG-A) gene 
[55-57].  Affected progeny cells are incapable of synthesizing the 
glycosylphosphatidylinositol (GPI)-anchor, and present the typical phenotype 
lacking from their surface all GPI-anchored proteins (GPI-AP). The abnormality 
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affects all hematopoietic lineages; a mutation occurred in a single HSC may sustain 
hematopoiesis even lifelong. It is well known that PNH red cells have an intrinsic 
susceptibility to complement-mediated hemolysis, due to the lack from their surface 
of the GPI-AP complement inactivator CD59 [55]; this leads to the intravascular 
hemolysis typical of PNH patients. However, other cardinal features of PNH, 
namely propensity to venous thrombosis and bone marrow failure, remain unclear, 
as well as the reasons for the PNH clone expansion [55,58].  Thus, PNH is a true 
disease of the HSC, as marked by the PIG-A mutation, but the HSC defect does 
not explain entirely the phenotype. In fact, a series of observations suggest that the 
PIG-A mutation is necessary but not sufficient to cause PNH.  
(i) The existence of a few (10-50 cells per million) circulating PNH granulocyte 
may be demonstrated also in healthy individuals by flow cytometry, and confirmed 
by a nested PCR technique identifying the specific PIG-A mutation [59,60].  
(ii) Lymphocytes with the PNH phenotype appeared in lymphoma patients 
during treatment with alemtuzumab (an antibody that recognizes a GPI-anchored 
protein) and disappeared at treatment interruption [61].  
(iii) Several murine knock-out models were developed to recreate the disease, 
but the expansion of the aberrant clone seen in PNH patients could not be 
reproduced [62-64].  Even in experiments employing embryonic stem cells, the 
PNH clone did not overcome normal hematopoiesis, suggesting that the PIG-A 
mutation itself did not confer any intrinsic proliferative advantage to PNH HSC [63-
64].  This has been confirmed by several in vitro data using PNH and wild-type 
hemopoietic progenitors obtained by PNH patients [55].  
(iv) PNH hematopoiesis may be in some cases oligo- rather than monoclonal, as 
initially supported by differential susceptibility to complement lysis [65,66] , then by 
flow cytometry [67] and finally confirmed by PIG-A sequencing [68]; this observation 
raised the question whether the expansion of more clones carrying the same 
functional defect, but molecularly heterogeneous, is compatible with a random 
process.  
On these bases, the hypothesis of a dual pathophysiology for PNH has been 
developed, which is also known as the “relative advantage” [69]  or the “escape” 
theory [70].  According to this theory, a mutation in the PIG-A gene might be a fairly 
common phenomenon, which has no biological consequences, because the 
mutated cell has no chance of expanding in presence of a vast majority of normal 
cells.  However, the presence of external conditions may alter this equilibrium, 
creating an environment permissive for the expansion of PNH clone(s). The nature 
of such external trigger may be inferred from the close clinical association between 
PNH and AA. An antigen-driven immune response specifically targeting the marrow 
tissue may be postulated; if the target on HSC membrane is a GPI-linked molecule, 
PNH HSC will escape this injury while normal HSC are killed. Several evidences of 
immune derangement in PNH have been produced; as for AA, oligoclonality of the 
T cell pool has been reported [71], and immunodominant pathogenic CTL clones 
may be detected in most PNH patients [41,44,72]. In rare cases, such expansion 
may be extremely large, phenotypically resembling a subclinical LGL proliferation 
[73]. It has been recently described that these effector T cells express in excess the 
activating isoforms of inhibiting superfamily receptors, which elicit a powerful 
cytolitic activity [74]. However, once again the most striking evidence comes from 
gene expression profiling: when HSC from PNH patients were separated according 
to the presence on surface of the GPI-AP, distinct patterns of gene expression were 
identified. Phenotypically normal (GPI-AP positive) CD34+ cells harbored diffuse 
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abnormalities of their transcriptome, with over-expression of genes involved in 
apoptosis and immune activity, paralleling the findings seen in CD34+ cells of AA 
patients. By contrast, phenotypically pathologic PNH CD34+ (GPI-AP negative) 
showed a gene expression profiling closer to that obtained in CD34+ cells from 
healthy individuals [75]. This finding strongly supports the presence of an immune 
attack to the hematopoietic stem/progenitor cells, which spares the PNH cells. The 
“escape” of PNH cells may be interpreted in various manners. Contradictory data 
have been produced on a putative differential sensitivity to inhibitory stimuli 
between normal and PNH cells; susceptibility to apoptosis has been reported 
increased, normal or decreased in different models. Recently, it has been shown 
that human cell lines carrying the PIG-A mutation are less susceptible to NK-
mediated killing compared to their normal counterpart [76]. In a more sophisticated 
model, GPI-deficient cells showed impairment in inducing primary and secondary 
stimulation of both antigen-specific and alloreactive T cells, providing experimental 
support for the hypothesis that the PNH clone could inefficiently interact with the 
immune system [77].  However, the actual mechanisms causing the escape are still 
elusive. They may include the absence of specific GPI-APs directly targeted by 
effector immune cells, or a protection due to the absence of important molecules 
involved in cell-cell interaction (e.g., accessory molecules). Alternatively, it may be 
hypothesized a broader impaired sensitivity to common effector mechanisms, which 
may be due to the lack of GPI-APs or to non specific structural changes of the raft 
structure in the outer surface. 
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Fig. 1 
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Fig. 2 
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GENETIC BACKGROUND AFFECTING IMMUNE SYSTEM FUNCTIONING   
 
Immunogenetic background resulting from predisposing complex traits can 
influence the quality of the immune response and shape certain clinical features of 
BMF. Examples of such immunogenetic factors are human leucocyte antigen (HLA) 
and killer-cell immunoglobulin-like receptor (KIR) genotypes, and cytokine and 
cytokine receptor gene single nucleotide polymorphisms (SNP). Several studies 
have provided evidence that some HLA alleles are associated with a constitutive 
predisposition to an exaggerated immune response. Moreover, the interaction 
between HLA class I molecules and killer cell immunoglobulin-like receptor (iKIR) is 
essential for human NK cell function. The interaction of inhibitory or stimulatory KIR 
variants with their matching KIR-ligands (KIR-L) modulates the immune response 
by suppressing or activating cytotoxicity. For example, KIR3DL2 recognizes HLA-
A3 and HLA11 allotypes. The KIR3DL1 requires the presence of the Bw4+ epitope 
for an effective binding. The KIR2DL1 recognizes HLA-Cw 2/4/5/6/15 allotype, 
termed C1, based on the lysine amino acid residues present at position 80, while 
KIR2DL2 and 2DL3 recognize the remaining HLA-C allotype termed C2 that carry 
an asparagine at position 80. In recent years, many single-nucleotide 
polymorphisms (SNPs) have been detected by gene sequencing, particularly within 
the promoter regions of these genes. Several of these SNPs may be associated 
with differential levels of gene transcription and consequently to the susceptibility to 
develop an autoimmune disease. 
For example, an association has been reported between SNPs located in the 
promoter region of Interleukin-10 (IL10) and increased risk of acute GvHD [78} and 
with a particular phenotype in Juvenile Rheumatoid Arthritis [79]. Tumor necrosis 
factor receptor polymorphisms and SNPs in the TNF-" gene promoters have been 
involved in the pathogenesis of several autoimmune disease, including RA [80] and 
MS [81]. In bone marrow failure the role of SNPs has also been investigated; in 
patients with AA and PNH a higher frequency of high secretor variants of 
proinflammatory cytokine like TNF-" and IFN-! has been reported [82-83]. Other 
polymorphisms of immunomodulatory receptors can also have similar functional 
consequences [84]. Cytotoxic T lymphocyte associated protein -4 (CTLA-4), 
expressed mainly on activated T cells, is a potent downregulator of T cell response. 
Presence of some genetic variants in exon 1 region can be related with reduced 
expression of CTLA-4 and influenced immune response. Association between this 
SNP and clinical outcome after allo-HSCT [85] and some diseases such as MS [86] 
and diabetes mellitus type 1 [87] have been described. CD16, also know as Fc! 
receptor III, plays a central role in NK cell activation, and his pholymorphisms may 
change the affinity for NK cells. The presence of SNP in the extracellular domain 2 
can modify the normal receptor function and increase autoimmune disease 
susceptibility. 
We hypothesize that the quality of the immune response and some clinical features 
of MDS can be associated with the prevalence of specific immunogenetic factors.  
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Killer cell immunoglobuline-like receptor 
 
Natural killer (NK) cells are regulated in part by inhibitory receptors that recognize 
MHC class I molecules [88-89] on normal cells. In human, inhibitory receptors that 
recognize MHC class I molecules (HLA-A, HLA-B, HLA-C) belong to the KIR 
(immunoglobuline-like receptor family). Evidence is emerging from disease-
association studies that KIR receptors can play beneficial roles in viral infections, 
such as HIV and HCV, but may also predispose to autoimmune diseases. Two 
main families of receptors on NK cells that recognize HLA class I antigen have 
been discovered: killer cell immunoglobuline-like receptors (KIR) and the 
CD94/NKG2 receptor system. The KIR genes are highly polymorphic [90-91], and 
the receptors have complex clonal expression patterns on NK cells. Although 
structurally different, KIR and CD94/NKG2 receptors families have both activatory 
and inhibitory receptors for HLA class I antigen. These receptors collaborate to 
monitor and to respond to changes in HLA class I antigen on cells of the body. 
Because of the complexities inherent in these NK cell receptors and the complex 
nature of HLA ligand, it was a considerable challenge to understand how these 
receptors work on NK cells to enable an immune response. There are 16 different 
KIR genes [92-94] that are encoded on chromosome 19q13.4. These receptors 
have high similarity and most of the anti-KIR antibodies recognize more than one 
gene product. KIRs contain either two or three immunoglobuline –like domains with 
either long (DL) or short (DS) cytoplasmic tails. Long-tailed receptors carry one or 
two immunoreceptor tyrosine-based inhibition motifs (ITIMs), which contribute to 
inhibitory signaling [fig.3]. Short tailed receptors have a lysine residue in their 
transmembrane domain which is required for pairing with the immunoreceptor 
tyrosine-based activation motifs (ITAM). Of the 16 genes, 7 encode for the 
inhibitory KIR receptors (3DL1-3, 2DL1-3, 2DL5), 6 genes encode for the activating 
KIR receptors (3DS1, 2DS1-5), one gene encodes for KIR2DL4 receptors with both 
inhibitory and activating function, and two genes are pseudogenes which do not 
encode a functional KIR receptor. Five of the inhibitor KIR receptors (3DL1, 3DL2, 
2DL1-3) recognize distinct motif on the HLA class I molecules which are 
ubiquitously expressed [90-95] on the surface of normal cells. The KIR2DL1 
recognizes HLA-Cw2/4/5/6/15 allotypes (termed C2 group) which carry a lysine at 
amino acid position 80. KIR2DL2 and 2DL3 recognize the remaining  of the HLA-C 
allotypes (Cw1/3/7/8-termed C1 group) which carry an asparagine at position 80. 
KIR3DL1 binds to the Bw4 epitope which is conserved on a third of HLA-B alleles. 
KIR3DL2 recognizes HLA-A3 and A11 allotypes. The KIR2DL4 receptor binds to 
the trophoblast-specific nonclassical class I molecules HLA-G and induces rapid 
interferon-! production which promotes vascularization of the maternal deciduas 
during early pregnancy [fig.4]. The interaction of inhibitory receptors with HLA class 
I ligands trigger signals that turn off NK cells. Therfore, by expressing HLA-A, B, 
and C molecules, normals cells are protected from NK cell lysis. Downregulation of 
HLA class I expression due to tumor transformation or viral infection relieves the 
inhibitory influence of NK cells, permitting NK cells to lyse these unhealthy target 
cells, a phenomenon first described as the “missing-self” hypotesis [fig. 5]. 
Futhermore, NK cells can also directly recognize unhealthy cells through their cell 
surface-activating receptors, which can enhance lysis by NK cells. 
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Fig. 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 15 
Fig. 4 
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Fig. 5 
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CYTOTOXIC T LYMPHOCYTE-ASSOCIATED MOLECULE-4 (CTLA-4) 
Naïve T cells require two signals to proliferate and differentiate. Signal one is 
antigen-specific and is generated by interaction of the T cell receptor (TCR) with an 
antigen peptide presented on the MHC molecule. Signal two, essential in T cells for 
a functional response, is transduced most commonly through interaction of CD28 
on the T cell with B7 [96-98] on the antigen presenting cell [fig.6]. Expression of 
cytotoxic T lymphocyte-associated molecule-4 (CTLA-4) is subsequently up-
regulated on T cells activated in this manner. CTLA-4 is a negative regulator of T-
cell activation. Mice deficient in CTLA-4 develop a lymphoproliferative disorder 
resulting in premature death. The CTLA-4 gene in humans is located on 
chromosome 2q33 and is a prime candidate autoimmunity gene, as mutations 
within this gene lead to alterations in function that could have profound effects on 
the immune system. Expression of CTLA-4 appears to be selectively induced in 
certain pathological conditions; there are evidences that cell-surface expression of 
CTLA-4 protein is influenced by common polymorphisms in promoter and first-exon 
sequences. Defective CTLA-4 expression could results in failure to terminate T cell 
activation, leading to an inappropriate and prolonged T-cell response. 
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Fig. 6 
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Fc!  receptor IIIa (CD16) 
Receptor for IgG (FC!R) are important regulatory molecules of inflammatory 
responses [fig.7]. The human leukocyte Fc!R family consists of three major 
classes: CD64 (Fc!RIA, IB and IC); CD32 (Fc!RIIA, IIB and IIC); and CD16 
(Fc!RIIIA and IIIB) all mapped to the long arm of chromosome 1. The heterogeneity 
of Fc!R has functional consequences, as reflected in their specific cell distribution 
patterns and initiation of specific signaling pathways [99-101]. Functional 
polymorphisms of three Fc!R subclasses, further increase molecular heterogeneity, 
and cause inter-individual differences in the efficacy of Fc!R function. These 
differences may contribute to susceptibility or disease course of auto-immune and 
infectious diseases. Fc!RIIIA is expressed on macrophages and a subset of 
monocytes, NK-cells and !#-T-cells. Functional polimorphysms in this gene may 
determine the level of receptor interaction with IgG1, IgG3 and IgG4, as well as the 
efficiency of IgG-induced effector function. 
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Fig. 7 
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CYTOKINE AND CYTOKINE GENES 
 
Proinflammatory cytokines [102,104] and their related receptors and inhibitors 
(intereleukin-1 {IL-1, IL-1r,IL-1ra, IL-2, IL-6}, tumor necrosis factor " {TNF-"}, and 
IL-10) have been implicated in a number of immunological diseases [fig.8]. An initial 
insult provokes an inflammatory response and release of IL-1 and TNF-". The 
subsequent cascade of cytokine production initiates tissue damage. TNF-"  
mediates a variety of functions [105,106] and exerts markedly diverse effects on the 
immune system, which include regulation of MHC class II molecules dependent on 
cell differentiation [107-108] and promotion of self-tolerance in the early induction 
phase of some diseases. The gene encoding the proinflammatory cytokine TNF-" 
is located within the MHC locus on chromosome 6. IL-10 is a potent 
immunosuppressant [109-110] produced by monocytes, macrophages, T cells, B 
cells, dendritic cells, mast cells and eosinophilis. As a T-cell helper type 2 (Th2) 
cell-derived cytokine, IL-10 has been shown [103] to inhibit the secretion of Th1 
cell-derived cytokines (TNF-", IL-1", IL-1$, IL-6, IL-12, and IFN-!), limit the 
inflammatory responses and regulate the differentiation and proliferation of several 
immune cells such as T cells, B cells, Nk cells and antigen-presenting cells. IL-10 
also downregulates the expression of major histocompatibility complex (MHC) and 
costimulatory molecules; by these mechanisms it may attenuate alloreactive T-cell 
responses. The gene encoding IL-10 has been identified on chromosome 1q31-32. 
IFN-!, a lymphokine  produced by activated T cells [111,114], is an important 
regulatory molecule of the immune system and has been implicated [115] in the 
pathogenesis of multiple sclerosis, diabetes mellitus, and other autoimmune 
disease. 
Given this complexity of regulation of the immune system and all the possible 
players involved, we decided to study all genetically determined factors in a large 
cohort of BMF patients, including cases of AA, PNH and MDS. Specific 
polymorphisms affecting all these pathways were found associated with specific 
diseases which have an immune derangement in their pathophysiology. In our work 
we investigated the hypothesis that similar immunogenetic predisposition may be 
found in all or specific subtypes of BMFs. 
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Fig. 8 
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MATERIALS AND METHODS 
 
Patients 
Informed consent was obtained for peripheral blood collection according to the 
protocols approved by the Institutional Review Board of the Cleveland Clinic 
Foundation from 129 patients with MDS, and 77 patients with AA [tab.1 and 2]. 
MDS was diagnosed according to the WHO criteria. Twenty-one patients had 
refractory anemia (RACMD), 37 refractory anemia with ringed sideroblasts 
(RARS/RCMD-S) and 44 refractory anemia with blast excess (RAEB) OR 
secondary AML (sAML). Among the 77 patients with BMF 44 had a typical AA, 19 
had a co-presence of a small PNH clone and 14 had typical PNH. The hypoplastic 
features (n=10) were supported in all cases by bone marrow histological evaluation. 
The control group comprised 60 internal healthy controls and a large historical 
control cohort. 
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Table 1. BMF PATIENTS CHARACTERISTICS 
 
                                                    N 
 
                          AA                              44 
Diagnosis         AA/PNH                     19 
                          PNH                           14 
 
 
                             POS                           30 
DR 15                NEG                           36 
                          NA                              11 
 
 
 
                          Yes                             15 
Thrombosis       
                          Not                              62 
 
 
                          Yes                             46 
Treatment 
                          Not                              31 
 
 
                          Yes                             30 
Response 
                          Not                             16
 25 
 
Table 2. MDS PATIENTS DIAGNOSIS 
 
RA/RCMD=      21   
 
RARS/RCMD= 37  
 
RAEB/sAML=   44  
 
CMML=            11    
   
5q-   =                3 
 
MDS/MPD-U= 13    
     
 
 
 
 
 
 
 
Table 3. MDS PATIENTS CYTOGENETIC 
 
NORMAL KARYOTYPE             21   
 
COMPLEX KARYTOTYPE         37  
 
TRISOMY 8                                44  
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DNA extraction 
DNA was extracted from whole blood using the PureGene system (Gentra, 
Minneapolis, MN, USA). Samples were re-suspended in reduced Tris-EDTA buffer 
and the concentration was measured using a ND-1000 spectrophotometer 
(Nanodrop Technologies, Wilmington, DE, USA). 
 
 
 
HLA and KIR typing 
HLA class I and II typing was performed by PCR-sequence specific primers (PCR-
SSP) (Allogen Laboratories, Cleveland, OH, USA). KIR genotyping was performed 
using PCR-SSP to identify the presence or absence of KIR genes (Dynal Biotech; 
Invitrogen, Carlsbad, CA, USA). Locus-specific primer sets were utilised to amplify 
1·5 µg of genomic DNA for each sample. Genomic DNA was mixed with KIR PCR 
reaction buffer containing dNTPs and Taq DNA Polymerase, then applied to a 96-
well tray containing 5 µl optimised primer solution for thermal cycling. (Detailed 
description of this SSP amplification based method was reported by Gomez-Lozano 
& Vilches, 2002; Hsu et al, 2002; Marsh et al, 2003. Following amplification, PCR 
products were loaded on a 2% agarose gel containing 8 µl ethidium bromide. Upon 
completion of electrophoresis, the gel was photographed and interpreted. A KIR 
profile for each patient and control subject was determined by detecting the 
presence or absence of specifically amplified KIR products in each of 21 lanes 
containing individual allele-specific KIR primers. The KIR genes, 2DL1, 2DL2, 
2DL3, 2DL4, 2DL5, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3, 3DS1 
and pseudogenes 2DP1 and 3DP1 were studied [fig.9]. 
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Fig. 9 
 
 
 
 
 
 
 
 
 
 
 
 
KIR genotype Allele Specificity
2DL1 001/002
2DL2 001-005
2DL3 001-006
2DS1 001-004
2DS2 001/005
2DS3 002/004/007
2DS4 003/006
2DS4 00101/00102
2DS5 001-005
3DL1 00101-0012
3DS1 010-01301
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KIR and KIR-L assignment 
Ligands for KIR3DL2, 3DL1, 2DL1, 2DS1, 2DL2, 2DL3 and 2DS2 are known [116]. 
For the purpose of this study, KIR mismatch was defined as the presence of a 
specific KIR gene and the lack of its corresponding HLA ligand according to the 
method proposed by Parham (2005). For example, KIR3DL2 recognizes the A3 
and/or A11 allotypes. Consequently, lack of HLA-A3 or HLA-A11 combined with the 
presence of KIR3DL2 can be considered a KIR3DL2 mismatch. Similarly, KIR3DL1 
interacts with the Bw4 epitope; presence of two Bw6 epitopes combined with 
KIR3DL1 expression would result in KIR3DL1 mismatch. 
KIR2DL2, 2DL3, and thus 2DS2 and 2DS3 all interact with group 1 HLA-C 
molecules, which have a Lys residue in position 80 
(http://www.dorak.info/hla/c1c2.html). HLA-Cw 1, 3, 7, 8, 12, 13, 14 and 16 alleles 
make up HLA-C1. The presence of any of these three KIR genes and the absence 
of a group 1 HLA-C allele will result in a mismatch. Similarly, KIR2DL1 and 2DS1 
interact with group 2 HLA-C molecules, those having an Asn residue in position 80. 
The presence of any of the HLA-Cw alleles, Cw2, 4, 5, 6, 15, 17 and 18 would 
silence KIR2DL1 and 2DS1. For example, a patient whose HLA profile shows HLA 
Cw3, Cw7 would show KIR ligand HLA C1/C1 constellation; Cw2, Cw 4 would 
translate into KIR ligand C2/C2 constellation, both making a theoretical KIR/KIR-L 
mismatch possible. 
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Cytokine genotyping 
An assay designed for the detection of SNP in 13 different cytokine genes was 
used to create a cytokine SNP profile of MDS patients (Dynal Biotech; Invitrogen, 
Carlsbad, CA, USA). Sequence-specific oligonucleotide primers for amplification of 
specific alleles from IL1a, IL1b, IL1R, IL1RA, IL4Ra, IL12, IFN$, TGFb, TNFa, IL2, 
IL4, IL6, and IL10 were used [fig.10]. Primer pairs for the amplification of a target 
sequence are provided for a total of 48 PCR reactions for sample. Following the 
PCR, amplified DNA fragments were electrophoresed on a 2% agarose gel with 
8 µl ethidium bromide. Positive reactions for a specific allele were discerned by the 
presence of a band between the larger internal control band and the smaller primer 
dimer band [fig.11]. 
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Fig. 10 
 
 
 
 
 
 
 
 
 
 
 
Cytokine genotype Allele Specificity
IL1 -899 T/C
IL1 -511 C/T, +3962 T/C
IL1R Pst1 1970 T/C
Il1RA Mspa1 11100 T/C
IL4R +1902 G/A
IL12 -1188  C/A
IFN +874   A/T
TGF 1 Codon 10 C/T, codon 25 
G/C
IL2 -330 T/G, +166 G/T
IL4 -1098 T/G, -590 T/C, -33T/C
TNF -308 G/A, -238 A/G
IL6 -174 G/C, NT565 G/A
IL10 -1082 G/A, -819 C/T, -592 
C/A
CTLA-4  +49 A/G 
nt 559 G/T 
CD45 +77 C/G, +138 A/G 
 31 
Fig.11 
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CTLA4 PCR and sequencing 
Exon I of the CTLA-4 gene was amplified from total genomic DNA using sense 
primer 5'-catcgtcattgtagctaagc-3' and antisense primer 5'-tactcaagccgattagc-5' in a 
total volume of 25 µl. After initial denaturation at 94°C for 5 min, 30 cycles of 94°C 
for 30 s, 57°C for 35 s and 72°C for 40 s were performed. PCR products were 
purified and 3 µl were used in a sequencing reaction with 1 µl of BigDye (Applied 
Biosystems, Foster City, CA, USA) 1 µl of 3 µmol/l primer in a total volume of 10 µl; 
products were purified and run on ABI 7500 Sequencer as described previously 
[117]. 
 
 
Fc!RIIIa – 158V/F genotyping 
Allele-specific amplification of the Fc!RIIIa gene (FCGR3A) was performed as 
previously described with minor modifications [118]. Briefly, the PCR reaction was 
optimised using 50 ng of template DNA, 10 pmol of valine-specific or 
phenylalanine-specific primers, 2·5 mmol/l dNTPs, 2·5 mmol/l MgCl2 and 1 U Taq 
polymerase diluted in PCR buffer (Invitrogen) to a final volume of 25µl. For PCR 
amplification, an initial denaturation step of 5 min at 95°C was followed by 35 cycles 
(94°C for 30 s, 60°C for 30 s, 72°C for 30 s) and final extension at 72°C for 8 min. 
Samples were run in pairs using either G allele-specific (5'-ctgaagacacatt-
tttactcccaac-3') or T allele-specific (5'-ctgaagacacatttttactcccaaa-3') reverse primers 
combined with an Fc!RIIIa-specific forward primer (5'-tccaaaagccacactcaaagac-3'). 
The PCR products of 73 base pairs in the T or G allele-specific reaction were 
separated on 2·5% agarose gels and visualised under ultra-violet light using 
BioRad ChemiDoc XRS. Subjects were classified as heterozygous (VF), or 
homozygous (VV or FF). Ambiguous results were resolved by nucleotide 
sequencing. 
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RESULTS 
 
 
Distribution of HLA KIR-L and KIR genotypes 
We looked for significant differences in the frequency of individual HLA alleles in 
patients in comparison with the normal population. We noted that in AA as well as 
in MDS patients positive for both A3 and A11 alleles were decreased compared to 
normals (0% vs 9%, p= .01). Analysis of the HLA-B haplotypes Bw4 and Bw6, and 
of the HLA-C haplotype C1 and C2, did not reveal any significant deviation in the 
KIR ligand distributions between patients and control groups (table 3 and 4). We 
also determined the KIR genotype defined as the absence or presence of some 
KIR genes in patients and controls. For this analysis we performed an SSP PCR for 
the full panel of KIR genes. The frequency of the KIR genes present in the BMF 
population was compared to controls. KIR genotype of MDS patients did not 
significantly differ from healthy controls. However, when patients with AA were 
compared to controls, we found a decreased frequency of the inhibitory KIR2DL3  
(68% vs 88%, p=.0002). Similar differences (table 5 and 6) in the KIRs frequency 
were found between controls and MDS patients with associated cytopenia (63% vs 
88%, p=.02) who also showed increased frequency of the activating KIR2DS5 
compared to controls (66% vs 26%, p=.01).  
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Table 3. HLA DISTRIBUTION IN 91 AA PATIENTS AND IN 126 NORMAL 
CONTROLS 
 
 
 
 
HLA-A                   AA          %               controls         %                   p 
3/11     +/+      0   0 11 9.1 0.01 
3/11     +/-      40 44 46 36.4  
3/11    -/-      51 56 69 54.5  
HLA-B                
Bw4/Bw4       9 10 18 14.3 0.5 
Bw4/Bw6      47 51 57 45.2  
Bw6/Bw6       35 38 51 40.5  
HLA-C                
C1/C1     41 45 42 33.3 0.1 
C1/C2     34 38 54 42.9  
C2/C2     15 17 30 23.8  
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Table 4. HLA DISTRIBUTION IN 56 PATIENTS WITH MDS AND 126 NORMAL 
CONTROLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HLA-A                MDS              %          controls          %                 p 
3/11     +/+      0   0 11 9.1 0.008 
3/11     +/-      13 24 46 36.4  
3/11    -/-      43 75 69 54.5  
HLA-B                 
Bw4/Bw4       14 25 18 14.3 0.5 
Bw4/Bw6       29 52 57 45.2  
Bw6/Bw6       13 23 51 40.5  
HLA-C                 
C1/C1      25 43 42 33.3 0.3 
C1/C2      17 31 54 42.9  
C2/C2      14 26 30 23.8  
 36 
Table 5. KIR GENOTYPE DISTRIBUTION IN AA PATIENTS COMPARED TO 
NORMAL CONTROLS 
 
  
KIR 
genotype 
AA %  
(n=51) 
CTRL n CTRL  % KIR 
phenotype 
P value 
2DL1 81 281 94.6 inhibitory 0.001 
2DL2 53 157 52.9 inhibitory 1 
2DL3 68 262 88.5 inhibitory 0.0002 
2DS1 29 104 35 activating 0.5 
2DS2 53 142 48 activating 0.5 
2DS3 33 72 24.2 activating 0.2 
2DS4 92 285 96 activating 0.2 
2DS5 29 76 26 activating 0.7 
3DL1 90 287 96.6 inhibitory 0.004 
3DS1 47 101 34 activating 0.1 
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Table 6. KIR GENOTYPE DISTRIBUTION IN PATIENTS WITH MDS COMPARED 
TO NORMAL CONTROLS 
 
KIR genotype MDS %       
(n=85) 
CTRL n CTRL % KIR 
phenotype 
P value 
2DL1 96.9 281 94.6 inhibitory 0.4 
2DL2 56 157 52.9 inhibitory 0.6 
2DL3 87 262 88.5 inhibitory 0.7 
2DS1 49 104 35 activating 0.06 
2DS2 53 142 48 activating 0.4 
2DS3 28 72 24.2 activating 0.5 
2DS4 91 285 96 activating 0.09 
2DS5 34 76 26 activating 0.3 
3DL1 95 287 96.6 inhibitory 0.6 
3DS1 38 101 34 activating 0.5 
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KIR LIGAND GENOTYPE DISTRIBUTION 
In the next step of experiments, we studied the frequency of KIR mismatch in BMF. 
With this analysis we detected that in the AA population there was a decreased 
frequency of the 2DS1/C1 mismatch compared to the normal controls ( 14% vs 
44%, p=.003) (table 7). Moreover, in the MDS population we found a decreased 
frequency of the 2DS2/C2 mismatch and of the 3DL1/Bw4 mismatch compared to 
controls (17% vs 44%, p=.01 and 18% vs 47%, p=.0003, respectively) (table 8). 
Interestingly, when we performed the same analysis grouping MDS patients 
according to the IPSS score (table 9) based on the grade of the dysplasia, we 
found that patients with high risk MDS had increased frequency of the 2DL3/C1 
mismatch compared to the low risk MDS population (43% vs 12%, p=.006)  
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Table. 7 KIR- KIR LIGAND MISMATCH IN AA PATIENTS COMPARED TO 
NORMAL CONTROLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KIR-HLA 
Mismatch 
function Mismatched 
control        
 
   n          % 
Mismatched 
AA 
 
  n            % 
P 
value 
2DL1/C2 inhibitory 31/85    (36) 28/51     (55) 0,3 
2DL2/C1 inhibitory 6/53      (11) 2/51       (4) 0,1 
2DL3/C1 inhibitory 13/79    (16) 4/51       (8) 0,1 
2DS1/C2 activating 11/25    (44) 7/51       (14) 0,003 
2DS2/C1 activating 5/52      (10) 1/51       (2) 0,3 
3DL1/BW4 inhibitory 43/92   (46.7) 20/51     (39) 0,3 
3DL2/A3 or A11 inhibitory 54/93    (58) 28/51     (55) 0,7 
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Table. 8 KIR- KIR LIGAND MISMATCH IN MDS PATIENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KIR-HLA 
Mismatch 
function Mismatched 
control    
   
 n            % 
Mismatched 
patients 
  
n            % 
P value 
2DL1/C2 inhibitory 31/85    (36) 22/57    (38) 0,7 
2DL2/C1 inhibitory 6/53      (11) 7/57      (12) 0,8 
2DL3/C1 inhibitory 13/79    (16) 14/57    (24) 0,2 
2DS1/C2 activating 11/25    (44) 10/57    (17) 0,01 
2DS2/C1 activating 5/52      (10) 7/57      (12) 0,6 
3DL1/BW4 inhibitory 43/92    (46.7) 10/57    (18) 0,0003 
3DL2/A3 or A11 inhibitory 54/93    (58) 42/57    (74) 0,05 
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Table. 9 KIR- KIR LIGAND MISMATCH IN MDS SUBGROUPS 
 
 
 
 
KIR-HLA 
Mismatch 
function Low risk 
Tot % 
High risk 
Tot % 
2DL1/C2 inhibitory 13 (38) 9 (39) 
P value  0.8 0.8 
2DL2/C1 inhibitory 3 (9) 4 (17) 
P value  0.7 0.4 
2DL3/C1 inhibitory 4 (12) 10 (43) 
P value  0.5 0.006 
2DS1/C2 activating 6 (17) 4 (17) 
P value  0.02 0.04 
2DS2/C1 activating 3 (9) 4 (17) 
P value  0.9 0.3 
3DL1/BW4 inhibitory 6 (18) 4 (17) 
P value  0.3 0.1 
3DL2/A3 or A11 inhibitory 24 (70) 18 (78) 
P value  0.1 0.07 
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Cytokine and cytokine receptor SNP  
No significant differences in the MDS cohort compared to control for SNPs in IL1a, 
IL1b, IL1R, IL1RA, IL4Ra, IL12, IFN$, IL2, IL4 and IL6 were found. However, when 
we examined the frequency of the TGF-# genotype, the MDS chort showed a 
higher rate of the TT codon 10 variant (59% vs 32% in controls, p=.002) and higher 
rate of the GG codon 25 variant (71% vs 35% in controls, p=.0001). Since we 
already know that the combination of TT at codon 10 and GG at codon 25 is 
consistent with a “high secretor phenotype”, we also decided to analyze the 
secretor phenotype and found that in MDS patients there was a higher incidence of 
the high secretor phenotype  compared to controls (58% vs 31%, p=.004) [fig.12]. 
Heightened immune response could result in similar hematopoietic suppression as 
observed in AA, and lead to hypoplasia. Consequently, we subdivided MDS 
patients according to marrow cellularity and found that patient with the hypoplastic 
variant of MDS (n=10) were characterized by a higher prevalence of IL10 -819 T/T 
and –592 A/A phenotypes (40% vs 12% p=.03), which are functionally associated 
with a lower secretion [fig.13]. This phenotype may be related with less blocking 
activity on the synthesis of inflammatory cytokines. An analogous observation was 
also made for the T/T genotype of TGF-#  in patients with hypocellular MDS [fig.14]. 
In addition, looking to subgroup analysis, we found a higher incidence of the AG/AG 
haplotype for the TNF-" gene in high risk MDS [fig.15], consistent with high 
secretory phenotype (13% vs 1% p=.02). When we analyzed the AA cohort, in 
contrast to a few smaller studies, no association was found for SNPs in IL-4R", IL-
12, IL-1#, IL-2, IL-1", and TNF- ". However, like in the MDS cohort, when we 
examined the frequency of TGF-#  genotypes, an increased frequency of GG 
variant on codon 25 (61% vs 35% in controls, p=.03), consistent with an high 
secretory phenotype, was found [fig.16]. This difference was even more significant 
for patients with typical PNH. In addition, we found a lower incidence of TT 
genotypes for the IL1RA gene (33% vs 62% p=.02). According with the data 
previously published we confirm that the frequency of the hypersecretory genotype 
T/T of the INF-! was markedly over represented in the AA cohort compared to 
normal controls (28% vs 10%, p=.02) [fig.17]. When we compared the subgroup of 
the AA cohort based on the presence or not of a PNH clone, we interestingly found 
that the presence of a PNH clone seems to be related with the T/T genotype of IFN-
! phenotype (35% vs 14% p=.01).  
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Fig. 12 
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Fig. 13 
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Fig.14 
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Fig.15 
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Fig. 16 
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Fig. 17 
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DISCUSSION 
 
Because  a number of HLA class I alleles has been identified as ligand of KIR, it is 
possible to examine the frequency of ligand classes in various diseases. When we 
compared patients with AA, PNH and MDS with controls for the distribution of KIR-L 
groups, we found that in AA as well as in the MDS chort patients positive for both 
the A3 and A11 alleles were very low compared to normals. KIR genotyping 
(defined as absence or presence of specific KIR genes in patiens versus controls) 
revealed a significantly decreased frequency of the inhibitory KIR2DL3 in the AA 
population compared to normals; the fact that this inhibitor KIR is underrepresented 
in AA may lead to increased intensity or derangement of the immune response. In 
the next step of experiments, we studied the frequency of KIR miscmatch, defining 
as mismatch the presence of a specif KIR and the lack of the corresponding HLA 
ligands. Alteration of these interactions may influence KIR’s activity and so be 
responsible for predisposition to some disease. We found that in AA patients there 
was decreased frequency of the 2DS1/C1 mismatch compared to normal controls, 
while in MDS patients we found decreased frequency of the 2DS2/C2 mismatch 
compared to controls. The decreased frequency of 2DS1 and 2DS2 mismatch may 
result in reduced silencing of cytotoxic activity. In addition we found that patients 
with high risk MDS had an increased frequency of the 2DL3/C1 mismatch 
compared to the low risk group. Increased 2DL3 and decreased 2DS2 mismatch 
both result in enhancment of cytotoxicity towards target cells,with marked 
imbalance between TCR-activated cell lysis and KIR inhibition of cytotoxic immune 
response. Futher studies are needed to assess whether these alteration in KIR and 
KIR-L occurring at genetic level actually translate into functional consequences, 
possibly resulting in increased disease susceptibility. In addition to HLA and KIR 
backgroud, other immunogenetic factors may play a role in the pathogenesis of 
BMF. For example, various cytokines involved in inflammation and apoptosis 
pathways could play a role in the intricate relationship between genetic 
determinants of immune response and BMF clinical course. We have empirically 
selected a number of cytokine and cytokine promoters and receptors 
polymorphisms that have been described to play a role in various autoimmune 
disease.We found that in MDS patients there was a higher frequency of the high 
secretor phenotype of TGF-$ compared to controls. In addition, looking to subgroup 
analysis, we found that in high risk MDS there was a higher frequency of the 
secretory phenotype of TNF-", compatible with increased inflammatory activity. 
This difference was even more significant for patients with typical PNH. Compared 
with normal, the AA cohort showed a incrased frequency of the hypersecretory 
phenotype of INF-!. We also found that the presence of a PNH clone was related 
with a high secretory phenotype of IFN-!. This finding support that the presence of 
a PNH clone may be a marker of immunomediated pathophysiology. The inhibitory 
ability of lymphocytes form AA patients has been explored intensively, and over-
expression of Th1 cytokines, leading to bone marrow damage, has been reported 
[119,120]. Moreover, TGF-$ is a well-known inhibitory factor in human models, and 
was found to be increased in PNH clone that emerged after Campath-1H therapy 
[121]. In summry our data, showing a genotypic profile associated wit high TGF-$ 
and IFN-! prodution in patients with bone marrow failure, are consistent with these 
findings, and suggest that genetic regulation of inflammatory and T-cell- mediated 
immunological pathways could be involved in the pathogenesis of bone marrow 
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failure, reinforcing the view that both AA and PNH are organ-specific autoimmune 
disorders.  
 
 
 
Bibliografia 
 
 
1. Gordon MY. Physiology and function of the haemopoietic microenvironment. 
Br J Haematol. 1994; 86: 241-3. 
2. Ogawa M, Porter PN, Nakahata T. Renewal and commitment to differentiation 
of hemopoietic stem cells (an interpretive review). Blood 1983; 61: 823-9. 
3. Kondo M, Wagers AJ, Manz MG, Prohaska SS, Scherer DC, Beilhack GF, 
Shizuru JA, Weissman IL. Biology of hematopoietic stem cells and 
progenitors: implications for clinical application. Annu Rev Immunol 2003; 21: 
759-806.  
4. Young NS. Acquired aplastic anemia. In: Young NS, ed. Bone marrow failure 
syndromes. Philadelphia, W.B. Saunders; 2000: 1-46. 
5. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. A severe and 
consistent deficit in marrow and circulating primitive hematopoietic cells (long-
term culture-initiating cells) in acquired aplastic anemia. Blood 1996; 88: 1983-
1991. 
6. Bacigalupo A, Piaggio G, Podesta M, Van Lint MT, Valbonesi M, Lercari G, 
Mori PG, Pasino M, Franchini E, Rivabella L, et al. Collection of peripheral 
blood hematopoietic progenitors (PBHP) from patients with severe aplastic 
anemia (SAA) after prolonged administration of granulocyte colony-stimulating 
factor. Blood 1993; 82: 1410-1414. 
7. Scopes J, Bagnara M, Gordon-Smith EC, Ball SE, Gibson FM. Haemopoietic 
progenitor cells are reduced in aplastic anaemia. Br J Haematol 1994; 86: 
427-430. 
8. Manz CY, Nissen C, Wodnar-Filipowicz A. Deficiency of CD34+ c-kit+ and 
CD34+38- hematopoietic precursors in aplastic anemia after 
immunosuppressive treatment. Am J Hematol 1996; 52: 264-274. 
9. Maciejewski JP, Kim S, Sloand E, Selleri C, Young NS. Sustained long-term 
hematologic recovery despite a marked quantitative defect in the stem cell 
compartment of patients with aplastic anemia after immunosuppressive 
therapy. Am J Hematol 2000; 65: 123-131. 
10. Schrezenmeier H, Jenal M, Herrmann F, Heimpel H, Raghavachar A. 
Quantitative analysis of cobblestone area-forming cells in bone marrow of 
patients with aplastic anemia by limiting dilution assay. Blood 1996; 88: 4474-
4480. 
11. Sutherland HJ, Eaves CJ, Eaves AC, Dragowska W, Lansdorp PM. 
Characterization and partial purification of human marrow cells capable of 
initiating long-term hematopoiesis in vitro. Blood 1989; 74: 1563-1570. 
12. Pettengell R, Luft T, Henschler R, Hows JM, Dexter TM, Ryder D, Testa NG. 
Direct comparison by limiting dilution analysis of long-term culture-initiating 
cells in human bone marrow, umbilical cord blood, and blood stem cells. Blood 
1994; 84: 3653-3659. 
 51 
13. Podesta M, Piaggio G, Frassoni F, Pitto A, Zikos P, Sessarego M, Abate M, 
Teresa VL, Berisso G, Bacigalupo A. The assessment of the hematopoietic 
reservoir after immunosuppressive therapy or bone marrow transplantation in 
severe aplastic anemia. Blood 1998; 91: 1959-1965. 
14. Rizzo S, Scopes J, Elebute MO, Papadaki HA, Gordon-Smith EC, Gibson FM. 
Stem cell defect in aplastic anemia: reduced long term culture-initiating cells 
(LTC-IC) in CD34+ cells isolated from aplastic anemia patient bone marrow. 
Hematol J 2002; 3: 230-236. 
15. Marsh JC, Chang J, Testa NG, Hows JM, Dexter TM. In vitro assessment of 
marrow 'stem cell' and stromal cell function in aplastic anaemia. Br J Haematol 
1991; 78: 258-267. 
16. Novitzky N and Jacobs P. Immunosuppressive therapy in bone marrow 
aplasia: the stroma functions normally to support hematopoiesis. Exp Hematol 
1995; 23:1472-1477. 
17. Novitzky N and Jacobs P. Marrow stem cell and stroma cell function in aplastic 
anaemia. Br J Haematol 1991; 79: 531-533. 
18. Philpott NJ, Scopes J, Marsh JC, Gordon-Smith EC, Gibson FM. Increased 
apoptosis in aplastic anemia bone marrow progenitor cells: possible 
pathophysiologic significance. Exp Hematol 1995; 23: 1642-1648. 
19. Killick SB, Cox CV, Marsh JC, Gordon-Smith EC, Gibson FM. Mechanisms of 
bone marrow progenitor cell apoptosis in aplastic anaemia and the effect of 
anti-thymocyte globulin: examination of the role of the Fas-Fas-L interaction. 
Br J Haematol 2000; 111: 1164-1169. 
20. Ismail M, Gibson FM, Gordon-Smith EC, Rutherford TR. Bcl-2 and Bcl-x 
expression in the CD34+ cells of aplastic anaemia patients: relationship with 
increased apoptosis and upregulation of Fas antigen. Br J Haematol 2001; 
113: 706-712. 
21. Young N and Maciejewski JP. Aplastic Anemia. In: Hoffman R, Benz EJJ, 
Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, ed. Hematology 
(Basic Principles and Practice). Philadelphia, Churchill Livingstone; 2000: 297-
330. 
22. Young NS. Acquired aplastic anemia. Ann Intern Med 2002; 136: 534-546. 
23. Young NS and Maciejewski J. The pathophysiology of acquired aplastic 
anemia. N Engl J Med 1007; 336: 1365-1372. 
24. Dufour C, Corcione A, Svahn J, Haupt R, Battilana N, Pistoia V. Interferon 
gamma and tumour necrosis factor alpha are overexpressed in bone marrow T 
lymphocytes from paediatric patients with aplastic anaemia. Br J Haematol 
2001; 115: 1023-1031. 
25. Sloand E, Maciejewski JP, Tisdale J, Follman D, Young NS. Intracellular 
Interferon-$ (IFN-$) in circulating and marrow T cells detected by flow 
cytometry and the response to immunosuppressive therapy in patients with 
aplastic anemia. Blood 2002; 100: 3129-3135. 
26. Sato T, Selleri C, Anderson S, Young NS, Maciejewski JP. Expression and 
modulation of cellular receptors for interferon-gamma, tumour necrosis factor, 
and Fas on human bone marrow CD34+ cells. Br J Haematol 1997; 97: 356-
365. 
27. Maciejewski JP, Selleri C, Sato T, Anderson S, Young T. Increased 
expression of Fas antigen on bone marrow CD34+ cells of patients with 
aplastic anaemia. Br J Haematol 1995; 91: 245-252. 
 52 
28. Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on 
CD34+ human marrow cells is induced by interferon gamma and tumor 
necrosis factor alpha and potentiates cytokine-mediated hematopoietic 
suppression in vitro. Blood 1995; 85: 3183-3190. 
29. Selleri C, Maciejewski JP, Sato T, Young NS. Interferon-gamma constitutively 
expressed in the stromal microenvironment of human marrow cultures 
mediates potent hematopoietic inhibition. Blood 1996; 87: 4149-4157. 
30. Marsh JC. Hematopoietic growth factors in the pathogenesis and for the 
treatment of aplastic anemia. Semin Hematol 2000; 37: 81-90. 
31. Callera F and Falcao RP. Increased apoptotic cells in bone marrow biopsies 
from patients with aplastic anaemia. Br J Haematol 1997; 98: 18-20. 
32. Nistico A and Young NS. gamma-Interferon gene expression in the bone 
marrow of patients with aplastic anemia. Ann Intern Med 1994; 120: 463-469. 
33. Marsh JC, Gibson FM, Prue RL, Bowen A, Dunn VT, Hornkohl AC, Nichol JL, 
Gordon-Smith EC. Serum thrombopoietin levels in patients with aplastic 
anaemia. Br J Haematol 1996; 95: 605-610. 
34. Dybedal I, Yang L, Bryder D, Aastrand-Grundstrom I, Leandersson K, 
Jacobsen SE. Human reconstituting hematopoietic stem cells up-regulate Fas 
expression upon active cell cycling but remain resistant to Fas-induced 
suppression. Blood 2003; 102: 118-126. 
35. Maciejewski JP, Selleri C, Sato T, Cho HJ, Keefer LK, Nathan CF, Young NS. 
Nitric oxide suppression of human hematopoiesis in vitro. Contribution to 
inhibitory action of interferon-gamma and tumor necrosis factor-alpha. J Clin 
Invest 1995; 96: 1085-1092. 
36. Selleri C, Sato T, Raiola AM, Rotoli B, Young NS, Maciejewski JP. Induction of 
nitric oxide synthase is involved in the mechanism of Fas-mediated apoptosis 
in haemopoietic cells. Br J Haematol 1997; 99: 481-489. 
37. Zeng W, Chen G, Kajigaya S, Nunez O, Charrow A, Billings EM, Young NS. 
Gene expression profiling in CD34 cells to identify differences between 
aplastic anemia patients and healthy volunteers. Blood 2004; 103: 325-332.  
38. Nakao S, Takami A, Takamatsu H, Zeng W, Sugimori N, Yamazaki H, Miura 
Y, Ueda M, Shiobara S, Yoshioka T, Kaneshige T, Yasukawa M, Matsuda T. 
Isolation of a T-cell clone showing HLA-DRB1*0405-restricted cytotoxicity for 
hematopoietic cells in a patient with aplastic anemia. Blood 1997; 89: 3691-
3699. 
39. Zoumbos N, Gascon P, Trost S, Djeu J, Young N. Circulating activated 
suppressor T lymphocytes in aplastic anemia. N Engl J Med 1985; 312: 257-
265. 
40. Kook H, Risitano AM, Zeng W, Wlodarski M, Lottemann C, Nakamura R, 
Barrett J, Young NS, Maciejewski JP. Changes in T-cell receptor VB repertoire 
in aplastic anemia: effects of different immunosuppressive regimens. Blood 
2002; 99: 3668-3675. 
41. Risitano AM, Kook H, Zeng W, Chen G, Young NS, Maciejewski JP. 
Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and 
paroxysmal nocturnal hemoglobinuria measured by V# CDR3 spectratyping 
and flow cytometry. Blood 2002; 100: 178-183. 
42. Plasilova M, Risitano A, Maciejewski JP. Application of the molecular analysis 
of the T-cell receptor repertoire in the study of immune-mediated hematologic 
diseases. Hematology 2003; 8: 173-181. 
 53 
43. Zeng W, Maciejewski JP, Chen G, Young NS. Limited heterogeneity of T-cell 
receptor VB usage in aplastic anemia. J Clin Invest 2001; 108: 765-773. 
44. Risitano AM, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS.  In 
vivo dominant immune responses in aplastic anemia patients: molecular 
tracking of putatively pathogenic T cells by TCR$-CDR3 sequencing.  Lancet 
2004; 364: 353-363. 
45. Brummendorf TH, Dragowska W, Lansdorp PM. Asymmetric cell divisions in 
hematopoietic stem cells. Ann N Y Acad.Sci 1999; 872: 265-272. 
46. Brummendorf TH, Rufer N, Holyoake TL, Maciejewski J, Barnett MJ, Eaves 
CJ, Eaves AC, Young N, Lansdorp PM. Telomere length dynamics in normal 
individuals and in patients with hematopoietic stem cell-associated disorders. 
Ann N Y Acad Sci 2001; 938: 293-303. 
47. Brummendorf TH, Maciejewski JP, Mak J, Young NS, Lansdorp PM. Telomere 
length in leukocyte subpopulations of patients with aplastic anemia. Blood 
2001; 97: 895-900. 
48. Chiu CP, Dragowska W, Kim NW, Vaziri H, Yui J, Thomas TE, Harley CB, 
Lansdorp PM. Differential expression of telomerase activity in hematopoietic 
progenitors from adult human bone marrow. Stem Cells 1996; 14: 239-248. 
49. Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JC, Gordon-Smith EC. 
Progressive telomere shortening in aplastic anemia. Blood 1998; 91: 3582-
3592. 
50. Lee JJ, Kook H, Chung IJ, Na A, Park MR, Hwang TJ, Kwak JY, Sohn SK, 
Kim HJ. Telomere length changes in patients with aplastic anaemia. Br J 
Haematol 2001; 112: 1025-1030. 
51. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct clinical 
outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 
2002; 99: 3129-3135. 
52. Maciejewski JP and Selleri C. Evolution of clonal cytogenetic abnormalities in 
aplastic anemia. Leuk Lymphoma 2004; 45: 433-40. 
53. Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y, Kaneko T, 
Takano T, Ikuta K, Tsukimoto I; Japan Childhood Aplastic Anemia Study 
Group. Risk factors for evolution of acquired aplastic anemia into 
myelodysplastic syndrome and acute myeloid leukemia after 
immunosuppressive therapy in children. Blood 2002; 100; 786-90. 
54. European Group for Blood and Marrow Transplantation (EBMT) Working Party 
on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo 
(GITMO). Bacigalupo A;Bruno B;Saracco P;Di Bona E;Locasciulli A;Locatelli 
F;Gabbas A;Dufour C;Arcese W;Testi G;Broccia G;Carotenuto M;Coser 
P;Barbui T;Leoni P;Ferster A. Antilymphocyte globulin, cyclosporine, 
prednisolone, and granulocyte colony-stimulating factor for severe aplastic 
anemia: an update of the GITMO/EBMT study on 100 patients. Blood 2000; 
95:1931-1934. 
55. Young NS and Maciejewski JP Genetic and environmental effects in 
paroxysmal nocturnal hemoglobinuria: this little PIG-A goes "Why? Why? 
Why?". J Clin Invest 2000; 106: 637-641. 
56. Luzzatto L, Bessler M, Rotoli B. Somatic mutations in paroxysmal nocturnal 
hemoglobinuria: a blessing in disguise. Cell 1997; 88: 1-4. 
57. Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, Takahashi M, Kitani 
T, Kinoshita, T.  Deficiency of the GPI anchor caused by a somatic mutation of 
 54 
the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993; 73: 703-
11. 
58. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of 
paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 1253-1258. 
59. Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of 
hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and 
phenotype are present in normal individuals. Proc Natl Acad Sci U S A 1999; 
96: 5209-5214. 
60. Hu R, Mukhina GL, Piantadosi S, Barber JP, Jones RJ, Brodsky RA. PIG-A 
mutations in normal hematopoiesis. Blood 2005; 105: 3848-54. 
61. Hertenstein B, Wagner B, Bunjes D, Duncker C, Raghavachar A, Arnold R, 
Heimpel H, Schrezenmeier H. Emergence of CD52-, 
phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo 
application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood 
1995; 86: 1487-1492. 
62. Rosti V, Tremml G, Soares V, Pandolfi PP, Luzzatto L, Bessler M. Murine 
embryonic stem cells without pig-a gene activity are competent for 
hematopoiesis with the PNH phenotype but not for clonal expansion. J Clin 
Invest 1997; 100: 1028-1036. 
63. Keller P, Payne JL, Tremml G, Greer PA, Gaboli M, Pandolfi PP, Bessler M. 
FES-Cre targets phosphatidylinositol glycan class A (PIGA) inactivation to 
hematopoietic stem cells in the bone marrow. J Exp Med 2001; 194: 581-589. 
64. Jasinski M, Keller P, Fujiwara Y, Orkin SH, Bessler M. GATA1-Cre mediates 
Piga gene inactivation in the erythroid/megakaryocytic lineage and leads to 
circulating red cells with a partial deficiency in glycosyl phosphatidylinositol-
linked proteins (paroxysmal nocturnal hemoglobinuria type II cells). Blood 
2001; 98: 2248-2255. 
65. Rosse WF, Dacie JV. Immune lysis of normal human and paroxysmal 
nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red 
cells to lysis by complement and specific antibody. J Clin Invest 1966;45:736-
748. 
66. Rotoli B, Robledo R, Scarpato N, Luzzatto L. Two populations of erythroid cell 
progenitors in paroxysmal nocturnal hemoglobinuria. Blood 1984; 64: 847-851. 
67. van der Schoot CE, Huizinga TW, van 't Veer-Korthof ET, Wijmans R, Pinkster 
J, von dem Borne AE. Deficiency of glycosyl-phosphatidylinositol-linked 
membrane glycoproteins of leukocytes in paroxysmal nocturnal 
hemoglobinuria, description of a new diagnostic cytofluorometric assay. Blood 
1990; 76: 1853-1859. 
68. Endo M, Ware RE, Vreeke TM, Singh SP, Howard TA, Tomita A, Holguin MH, 
Parker CJ.  Molecular basis of the heterogeneity of expression of glycosyl 
phosphatidylinositol anchored proteins in paroxysmal nocturnal 
hemoglobinuria. Blood 1996; 87: 2546-57. 
69. Rotoli B, Luzzatto L. Paroxysmal nocturnal haemoglobinuria. Baillieres Clin 
Haematol 1989; 2: 113-138. 
70. Dunn DE, LIU JM, Young NS. In: Young NS, ed. Bone marrow failure 
syndromes. Philadelphia, W.B. Saunders; 2000: 99-121. 
71. Karadimitris A, Manavalan JS, Thaler HT, Notaro R, Araten DJ, Nafa K, 
Roberts IA, Weksler ME, Luzzatto L. Abnormal T-cell repertoire is consistent 
with immune process underlying the pathogenesis of paroxysmal nocturnal 
hemoglobinuria. Blood 2000; 96: 2613-262 
 55 
72. Plasilova M, Risitano AM, O’Keefe CL, Rodriguez A, Wlodarski M, 
Maciejewski JP. Shared and individual specificities of immunodominant 
cytotoxic T cell clones in Paroxysmal Nocturnal Hemoglobinuria as determined 
by molecular analysis. Exp Hematol 2004; 32: 261-269.  
73. Risitano AM, Maciejewski JP, Muranski P, Wlodarski M, O'Keefe C, Sloand 
EM, Young NS. Large granular lymphocyte (LGL)-like clonal expansions in 
paroxysmal nocturnal hemoglobinuria (PNH) patients. Leukemia 2005; 19: 
217-22. 
74. Poggi A, Negrini S, Zocchi MR, Massaro AM, Garbarino L, Lastraioli S, 
Gargiulo L, Luzzatto L, Notaro R. Patients with paroxysmal nocturnal 
hemoglobinuria have a high frequency of peripheral-blood T cells expressing 
activating isoforms of inhibiting superfamily receptors. Blood 2005; 106: 2399-
408. 
75. Chen G, Zeng W, Maciejewski JP, Kcyvanfar K, Billings EM, Young NS. 
Differential gene expression in hematopoietic progenitors from paroxysmal 
nocturnal hemoglobinuria patients reveals an apoptosis/immune response in 
'normal' phenotype cells. Leukemia 2005; 19: 862-8. 
76. Nagakura S, Ishihara S, Dunn DE, Nishimura J, Kawaguchi T, Horikawa K, 
Hidaka M, Kagimoto T, Eto N, Mitsuya H, Kinoshita T, Young NS, Nakakuma 
H. Decreased susceptibility of leukemic cells with PIG-A mutation to natural 
killer cells in vitro. Blood 2002; 100: 1031-1037. 
77.   Murakami Y, Kosaka H, Maeda Y, Nishimura J, Inoue N, Ohishi K, Okabe M, 
        Takeda J, Kinoshita T. Inefficient response of T lymphocytes to 
        glycosylphosphatidylinositol anchor-negative cells: implications for paroxysmal   
        nocturnal hemoglobinuria. Blood 2002; 100: 4116-4122. 
78.   Lin MT, Storer B, Martin PJ, Tseng LH, Gooley T, Chen PJ, Hansen JA 
        Relation of an interleukin-10 promoter polymorphism to graft-versus-host     
disease and survival after hematopoietic-cell transplantation. N Engl J Med.  
2003 Dec 4;349(23):2201-10 
79.   Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I and Woo P. 
Polymorphic haplotype of the interleukin-10 5’ flanking region determine 
variable interleukin- 10 transcription and are associated with particular 
phenotype of juvanile rheumatoid arthtritis. Arthritis & Rheumatism. 1999 Jun; 
42 (6): 1101-1108 
80.    Kang CP, Lee KW, Yoo DH, Kang C, Bae SC. The influence of a 
polymorphism at position -857 of the tumour necrosis factor alpha gene on 
clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology 
(Oxford). 2005 Jun;44(6):705-7. 
81.    Search for genetic factors associated with susceptibility to multiple sclerosis. 
         Forte GI, Ragonese P, Salemi G, Scola L, Candore G, D'Amelio M, Crivello A,      
         Di Benedetto N, Nuzzo D, Giacalone A, Lio D, Caruso C. Ann N Y Acad Sci.    
         2006 May;1067:264-9. 
82.    Fermo E, Bianchi P, Barcellini W, Pedotti P, Boschetti C, Alfinito F, Cortelezzi 
A, Zanella A. Immunoregulatory cytokine polymorphisms in Italian patients 
affected by paroxysmal nocturnal haemoglobinuria and aplastic anaemia. 
         Eur J Immunogenet. 2004 Dec;31(6):267-9. 
83.    Gidvani V, Ramkissoon S, Sloand EM, Young NS. Cytokine gene 
polymorphisms in acquired bone marrow failure. Am J Hematol. 2007 
Aug;82(8):721-4. 
 
 56 
   84.     Levings MK, Bacchetta R, Schulz U, Roncarolo MG. The role of IL-10 and 
TGF-beta in the differentiation and effector function of T regulatory cells. Int 
Arch Allergy Immunol. 2002 Dec;129(4):263-76. Review. 
   85.     Markey KA, MacDonald KP, Hill GR. Impact of cytokine gene polymorphisms 
on graft-vs-host disease. Tissue Antigens. 2008 Dec;72(6):507-16. Epub 
2008 Sep 29. 
   86.     Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J. CTLA-4 gene 
expression is influenced by promoter and exon 1 polymorphisms. Genes 
Immun. 2001 May;2(3):145-52. 
   87.     Nisticò L, Buzzetti R, Pritchard LE, Van der Auwera B, Giovannini C, Bosi E, 
Larrad MT, Rios MS, Chow CC, Cockram CS, Jacobs K, Mijovic C, Bain SC, 
Barnett AH, Vandewalle CL, Schuit F, Gorus FK, Tosi R, Pozzilli P, Todd JA. 
          The CTLA-4 gene region of chromosome 2q33 is linked to, and associated    
         with, type 1 diabetes. Belgian Diabetes Registry.Hum Mol Genet. 1996  
         Jul;5(7):1075-80. 
88.    Gasser S, Raulet DH. Activation and self-tolerance of natural killer cells. 
         Immunol Rev. 2006 Dec;214:130-42. Review. 
89. Rajagopalan S, Long EO. Understanding how combinations of HLA and KIR 
        genes  influence disease. J Exp Med. 2005 Apr 4;201(7):1025-9. Review. 
90.    Du Z, Gjertson DW, Reed EF, Rajalingam R. Receptor-ligand analyses define 
         minimal killer cell Ig-like receptor (KIR) in humans. Immunogenetics. 2007 
         Jan;59(1):1-15. Epub 2006 Nov 14. 
91.    Howe EC, Wlodarski M, Ball EJ, Rybicki L, Maciejewski JP. Killer 
immunoglobulin-like receptor genotype in immune-mediated bone marrow     
         failure syndromes. Exp Hematol. 2005 Nov;33(11):1357-62. 
92.    Gardiner CM. Killer cell immunoglobulin-like receptors on NK cells: the how, 
where and why. Int J Immunogenet. 2008 Feb;35(1):1-8. Epub 2007 Dec 18.  
Review. 
93.    Hsu KC, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon JD,  
Bornhäuser M, Christiansen F, Gratwohl A, Morishima Y, Oudshoorn M,  
         Ringden O, van Rood JJ, Petersdorf E; KIR ligands and prediction of relapse  
After unrelated donor hematopoietic cell transplantation for hematologic    
         malignancy. 
94.    Hsu KC, Dupont B Natural killer cell receptors: regulating innate immune 
         responses to hematologic malignancy. Semin Hematol. 2005 Apr;42(2):91- 
         103. Review. 
95.    Nearman ZP, Wlodarski M, Jankowska AM, Howe E, Narvaez Y, Ball E, 
Maciejewski JP. Immunogenetic factors determining the evolution of T-cell 
large granular lymphocyte leukaemia and associated cytopenias. Br J 
Haematol. 2007 Jan;136(2):237-48. Epub 2006 Nov 30. 
96.    Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J CTLA-4 gene 
expression is influenced by promoter and exon 1 polymorphisms. Genes 
Immun. 2001 May;2(3):145-52. 
97.    Masterman T, Ligers A, Zhang Z, Hellgren D, Salter H, Anvret M, Hillert J.   
CTLA4 dimorphisms and the multiple sclerosis phenotype. J Neuroimmunol. 
2002 Oct;131(1-2):208-12. 
98.    Barton A, Myerscough A, John S, Gonzalez-Gay M, Ollier Worthington J. A 
single nucleotide polymorphism in exon 1 of cytotoxic T-  lymphocyte-
associated-4 (CTLA-4) is not associated with rheumatoid arthritis. 
 57 
 99.   Leppers-van de Straat FG, van der Pol WL, Jansen MD, Sugita. A novel 
PCR-based method for direct Fc gamma receptor IIIa (CD16) allotyping. J 
Immunol Methods. 2000 Aug 28;242(1-2):127-32. 
100. Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by   
monoclonal antibody-coated target cells. J Immunol Methods. 2005 
         Sep;304(1-2):88-99.   
  101.  Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier 
H, Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: 
influence of FCGR3A polymorphism on the concentration-effect relationship. 
           Cancer Res. 2004 Jul 1;64(13):4664-9. 
102.  Petersen SL, Madsen HO, Ryder LP, Svejgaard A, Dickmeiss E, Vindeløv LL. 
Cytokine gene expression in peripheral blood mononuclear cells and 
alloreactivity in hematopoietic cell transplantation with nonmyeloablative 
conditioning. Biol Blood Marrow Transplant. 2006 Jan;12(1):48-60.   
103.  Middleton PG, Taylor PR, Jackson G, Proctor SJ, Dickinson AM. Cytokine 
gene polymorphisms associating with severe acute graft-versus-host disease 
in HLA-identical sibling transplants. Blood. 1998 Nov 15;92(10):3943-8. 
104.  Selleri C, Maciejewski JP, Catalano L, Ricci P, Andretta C, Luciano L, Rotoli 
B. Effects of cyclosporine on hematopoietic and immune functions in patients 
with hypoplastic myelodysplasia: in vitro and in vivo studies. Cancer. 2002 
Nov 1;95(9):1911-22. 
105.  Kim TG, Pyo CW, Hur SS, Kim YK, Hwang HY, Youn JI, Kim TY. 
Polymorphisms of tumor necrosis factor (TNF) alpha and beta genes in 
Korean patients with psoriasis. Arch Dermatol Res. 2003 Apr;295(1):8-13. 
Epub 2003 Mar 13. 
  106.  Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, 
Tanizawa T, Kamiyama R, Hirokawa K. Overexpression of tumor necrosis 
factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from 
patients with myelodysplastic syndromes. Leukemia. 1997 Dec; 11(12):2049-
54. 
  107.  Mundle SD, Reza S, Ali A, Mativi Y, Shetty V, Venugopal P, Gregory SA, 
Raza A. Correlation of tumor necrosis factor alpha (TNF alpha) with high 
Caspase 3-like activity in myelodysplastic syndromes. Cancer Lett. 1999 Jun 
1;140(1-2):201-7 
  108.  Mundle SD, Ali A, Cartlidge JD, Reza S, Alvi S, Showel MM, Mativi BY, 
Shetty VT, Venugopal P, Gregory SA, Raza A. Evidence for involvement of 
tumor necrosis factor-alpha in apoptotic death of bone marrow cells in 
myelodysplastic syndromes. Am J Hematol. 1999 Jan;60(1):36-47. 
109.   Zhang X, Hei P, Deng L, Lin J. Interleukin-10 gene promoter polymorphisms      
and their protein production in peritoneal fluid in patients with endometriosis. 
Mol Hum Reprod. 2007 Feb;13(2):135-40. Epub 2006 Dec 18. 
110.  Lin MT, Storer B, Martin PJ, Tseng LH, Grogan B, Chen PJ, Zhao  LP,  
Hansen JA. Genetic variation in the IL-10 pathway modulates severity of 
acute graft-versus-host disease following hematopoietic cell transplantation: 
synergism between IL-10 genotype of patient and IL-10 receptor beta 
genotype of donor. Blood. 2005 Dec 1;106(12):3995-4001. Epub 2005 Aug 
18. 
108.  Zeng W, Miyazato A, Chen G, Kajigaya S, Young NS, Maciejewski JP. 
Interferon-gamma-induced gene expression in CD34 cells: identification of 
 58 
pathologic cytokine-specific signature profiles. Blood. 2006 Jan 1;107(1):167-
75. Epub 2005 Aug 30.    
   109.  Sloand E. Genetic polymorphisms and the risk of acquired idiopathic aplastic 
anemia. Haematologica. 2005 Aug;90(8):1009B. 
   110.  Coluzzi S, Biffoni M, Pasqualetti D, Perrone MP, Vaglio S, Rahimi H, Arista 
MC, Laurenti L, Cerretti R, Girelli G. Production of interferon-gamma by 
lymphocytes from paroxysmal nocturnal haemoglobinuria patients: 
relationship with clinical status. Br J Haematol. 2004 Mar;124(5):685-90. 
   111.  Risitano AM, Maciejewski JP, Selleri C, Rotoli B. Function and malfunction of 
hematopoietic stem cells in primary bone marrow failure syndromes. Curr 
Stem Cell Res Ther. 2007 Jan;2(1):39-52. Review. 
    112.  Levings MK, Sangregorio R, Galbiati F, Squadrone S, de Waal Malefyt R, 
           Roncarolo MG. IFN-alpha and IL-10 induce the differentiation of human type 
           1 T regulatory cells. J Immunol. 2001 May 1;166(9):5530-9. 
  113.  Maciejewski JP, Anderson S, Katevas P, Young NS. 
           Phenotypic and functional analysis of bone marrow progenitor cell 
compartment in bone marrow failure. Br J Haematol. 1994 Jun;87(2):227-34. 
  114.  Nisticò A, Young NS. gamma-Interferon gene expression in the bone marrow 
of patients with aplastic anemia. Ann Intern Med. 1994 Mar 15;120(6):463-9. 
  115.  Maciejewski JP, Selleri C, Sato T, Cho HJ, Keefer LK, Nathan CF, Young NS. 
Nitric oxide suppression of human hematopoiesis in vitro. Contribution to 
inhibitory action of interferon-gamma and tumor necrosis factor-alpha. J Clin 
Invest. 1995 Aug;96(2):1085-92. 
  116.  Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell 
receptors: new biology and insights into the graft-versus-leukemia effect. 
Blood. 2002 Sep 15;100(6):1935-47. Review. 
  117.  Wlodarski MW, O'Keefe C, Howe EC, Risitano AM, Rodriguez A, 
Warshawsky I, Loughran TP Jr, Maciejewski JP. Pathologic clonal cytotoxic 
T-cell responses: nonrandom nature of the T-cell-receptor restriction in large 
granular lymphocyte leukemia. Blood. 2005 Oct 15;106(8):2769-80. Epub   
2005 May 24. 
  118.   Leppers-van de Straat FG, van der Pol WL, Jansen MD, Sugita N, Yoshie H,  
Kobayashi T, van de Winkel JG. A novel PCR-based method for direct Fc 
gamma receptor IIIa (CD16) allotyping. J Immunol Methods. 2000 Aug 
28;242(1-2):127-32. 
  119.  Gascon P, Zoumbos NC, Scala G, Djeu JY, Moore JG, Young NS. 
         Lymphokine abnormalities in aplastic anemia: implications for the mechanism   
         of action of antithymocyte globulin. Blood. 1985 Feb;65(2):407-13. 
120. Geissler K, Kabrna E, Kollars M, Ohler L, Berer A, Burgmann H, Winkler S, 
Willheim M, Hinterberger W, Lechner K.Interleukin-10 inhibits in vitro 
hematopoietic suppression and production of interferon-gamma and tumor 
necrosis factor-alpha by peripheral blood mononuclear cells from patients with 
aplastic anemia. Hematol J. 2002;3(4):206-13. 
121. Fracchiolla NS, Barcellini W, Bianchi P, Motta M, Fermo E, Cortelezzi A. 
Biological and molecular characterization of PNH-like lymphocytes emerging 
after Campath-1H therapy. Br J Haematol. 2001 Mar;112(4):969-71. 
 
 
 
 
 59 
 
Elenco delle pubblicazioni in extenso 
 
1) “Double-negative regulatory T cells induce allotolerance when expanded 
after allogeneic haematopoietic stem cell transplantation”. 
McIver Z, Serio B, Dunbar A, O'Keefe CL, Powers J, Wlodarski M, Jin T, Sobecks 
R, Bolwell B, Maciejewski JP. 
Br J Haematol. 2008 Apr;141(2):170-8. Epub 2008 Mar 3. 
 
2) “Hemochromatosis-associated gene mutations in patients with 
myelodysplastic syndromes with refractory anemia with ringed sideroblasts”. 
Nearman ZP, Szpurka H, Serio B, Warshawksy I, Theil K, Lichtin A, Sekeres MA, 
Maciejewski JP. 
Am J Hematol. 2007 Dec;82(12):1076-9. 
 
3) “High serum leptin in patients with chronic graft-versus-host disease after 
hematopoietic stem cell transplantation”. 
Tauchmanovà L, Matarese G, Carella C, De Rosa G, Serio B, Ricci P, Lombardi G, 
Rotoli B, Colao A, Selleri C. 
Transplantation. 2004 Nov 15;78(9):1376-83 
 
4) “Short-term zoledronic acid treatment increases bone mineral density and 
marrow clonogenic fibroblast progenitors after allogeneic stem cell 
transplantation”. 
Tauchmanovà L, Ricci P, Serio B, Lombardi G, Colao A, Rotoli B, Selleri C. 
J Clin Endocrinol Metab. 2005 Feb;90(2):627-34. Epub 2004 Nov 16. 
 
5) “Involvement of the urokinase-type plasminogen activator receptor in 
hematopoietic stem cell mobilization”. 
Selleri C, Montuori N, Ricci P, Visconte V, Carriero MV, Sidenius N, Serio B, Blasi 
F, Rotoli B, Rossi G, Ragno P. 
Blood. 2005 Mar 1;105(5):2198-205. Epub 2004 Oct 19.  
 
6) “Late relapse of acute promyelocytic leukemia treated with all- trans 
retinoic acid and chemotherapy: report of two cases” 
Ferrara F, Selleri C, Mele G, Serio B, Palmieri S, Pocali B, Pane F, Rotoli B. 
Ann Hematol. 2004 Jul;83(7):484-6. Epub 2004 Jan 17. 
 
 
 60 
 
7) “Avascular necrosis in long-term survivors after allogeneic or autologous 
stem cell transplantation: a single center experience and a review”. 
Tauchmanovà L, De Rosa G, Serio B, Fazioli F, Mainolfi C, Lombardi G, Colao A, 
Salvatore M, Rotoli B, Selleri C. 
Cancer. 2003 May 15;97(10):2453-61. 
 
 
8) “Involvement of nitric oxide in farnesyltransferase inhibitor-mediated 
apoptosis in chronic myeloid leukemia cells”. 
Selleri C, Maciejewski JP, Montuori N, Ricci P, Visconte V, Serio B, Luciano L, 
Rotoli B. 
Blood. 2003 Aug 15;102(4):1490-8. Epub 2003 Apr 24. 
 
 
9) “Long-lasting bone damage detected by dual-energy x-ray absorptiometry, 
phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells 
after allogeneic stem cell transplantation”. 
Tauchmanovà L, Serio B, Del Puente A, Risitano AM, Esposito A, De Rosa G, 
Lombardi G, Colao A, Rotoli B, Selleri C. 
Journal of Clinical Endocrinology § Metabolism 87, 5058-5065, 2002. 
 
 61 
Elenco delle pubblicazioni in abstract 
 
 
 
1. High number of Fas Positive CD34+ cells and CD4+ expressing interferon-
g $in hypoplastic myelodysplasia impair progenitor growth which may be 
improved by cyclosporin-A.  C Selleri, L Catalano, P Ricci, B Serio, A Risitano, 
M Volpicelli, C Califano, JP Maciejewski, B Rotoli.  
      Haematologica,  86 (Suppl to n.10), 78, 2001. 
2. Inhibition of colony formation and apoptosis in chronic myeloid leukemia 
cells by farnesyltransferase inhibitors is not mediated trough the Fas/Fas-
ligand system.  
      C Selleri, P Ricci, A Risitano, L Luciano, R De Mattia, V Visconte, 
      B Serio, M Barone, M Rossi, JP Maciejewski, B Rotoli.      
      Haematologica,  86 (Suppl to n.10), 80, 2001. 
3. Mixed backbone oligonucleotide targeting R1a subunit of protein kinase A 
may induce growth inhibition and apoptosis of human primary chronic 
myeloid leukemia cells in vitro. 
      C Selleri,  P Ricci, L Luciano, R Caputo, R De Mattia, V Visconte, M  
      Barone, B Serio, G Tortora, B. Rotoli. 
      Haematologica,  86 (Suppl to n.10), 85, 2001. 
4. Dual energy X-ray absorpiometry and quantitative ultrasonometry for the 
evaluation of osteopenia and osteoporosis after allogeneic bone marrow 
transplantation. 
       L Tauchmanovà, A del Puente, A Esposito, G Nutile, M Volpicelli,  
       B Serio, A Severino, V Nuzzo, G Lombardi, B Rotoli, C Selleri.  
       Haematologica,  86 (Suppl to n.10), 191, 2001. 
5. Long lasting bone damage detected by dual energy x-ray absorptiometry, 
phalangeal osteosonogrammetry and in vitro growth of marrow stromal 
cells after allogeneic stem cell transplantation for hematological 
malignancies. 
      C Selleri, L Tauchmanovà, G De Rosa, B Serio, P Ricci, M  
      Esposito, A del Puente, A Esposito,  G. Lombardi, AM Colao, B 
      Rotoli. 
      Hematology Journal, 3 (Suppl 1), 13, 2002. 
6. Effects of cyclosporin-A on hematopoietic and immune functions in 
patients with hypoplastic myelodysplasia: in vitro and in vivo studies.  
      C Selleri, JP Maciejewski, L Catalano, P Ricci, C Andretta, B Serio,  
       V Visconte, M Esposito, B Rotoli.  
       Haematologica 87, (Suppl 1 to 9), 86, 2002. 
7. Long lasting bone damage detected by dual energy x-ray absorptiometry, 
phalangeal osteosonogrammetry and in vitro growth of marrow stromal 
cells after allogeneic stem cell transplantation  
      L Tauchmanovà, C Selleri, B Serio, A del Puente, S Padula, G De 
      Rosa, M Filippella, B Rotoli, AM Colao. 
     Journal of Endocrinological Investigation, 25 (Suppl to n° 6), 21,  
      2002. 
8. Involvement of nitric oxide in farnesyltransferase inhibitor-mediated 
apoptosis in chronic myeloid leucemia cells 
      C Selleri, N Montuori, P Ricci, V Visconte, B Serio, G Di Iorio, L  
 62 
      Luciano, JP Maciejewski, B Rotoli.  
      Haematologica,  88 (Suppl n.15), 40, 2003. 
9. Farnesyltransferase inhibitors induce apoptosis in acute myeloid leukemia 
cells via activation of inducible nitric oxide synthase and caspase-3 
without Fas, BCL-2 and P53 modulation.  
      C Selleri, N Montuori, F Pane, P Ricci, C Quintarelli, G Di Iorio, B 
       Serio, A Camera, V Visconte, F Salvatore, JP Maciejewski, B  
      Rotoli. 
      Haematologica,  88 (Suppl n.15), 177, 2003. 
10. Late relapse of acute promyelocytic leucemia treated with all-trans retinoic 
acid and chemotherapy: report of two cases.   
      G Mele, B Serio, S Calmieri, B Pocali, C Selleri, F Ferrara, B Rotoli.  
      Haematologica,  88 (Suppl n.15), 299, 2003. 
11. Endocrine disfunction during the first year after stem cell transplant for 
hematological malignancies. 
      G De Rosa, L Tauchmanovà, M Esposito, C Selleri, G Lombardi,  
      AM Colao, B Serio, B Rotoli. 
      Haematologica,  88 (Suppl n.15), 343, 2003. 
12. Tymic rebound after autologous bone marrow transplantation G De Rosa, 
M Esposito, B Serio, C Selleri, A Lucania, S Del Vecchio, B Rotoli. 
      Haematologica,  88 (Suppl n.15), 343, 2003. 
13. Severe deficit of clonogenic fibroblast progenitors may be involved in the 
persisten bone damage after allogeneic stem cell transplantation. 
        B Serio, L Tauchmanovà , P Ricci, G Di Iorio, G De Rosa, M  
        Esposito, A Colao, B Rotoli,  C Selleri. 
        Haematologica,  88 (Suppl n.15), 363, 2003. 
14. Reduced intensity stem cell transplantation does not improbe outcome for 
older patients with active hematologic malignancy at the time of transplant. 
      C Selleri, B Serio, G De Rosa, M Esposito, F Chiurazzi, A Camera, 
      L Catalano, L Luciano, M Picardi, B Rotoli. 
      Haematologica,  88 (Suppl n.15), 363, 2003. 
15. Effect of different treatments on bone mineral density in long-term 
survivors after allogeneic stem cell transplantation.  
      L Tauchmanovà, B Serio, G De Rosa, M Esposito, G Bifulco, G  
      Lombardi, A Colao, B Rotoli, C Selleri.  
      Haematologica,  88 (Suppl n.15), 364, 2003. 
16. Serum leptin is elevated after hematopoietic stem cell transplant, 
especially when chronic graft versus host disease is present. 
      C Selleri, L Tauchmanovà, A Colao, G Matarese, C Carella, G De  
      Rosa, B Serio, P Ricci, M Esposito, G Lombardi, B Rotoli. 
      Haematologica,  88 (Suppl n.15), 365, 2003. 
17. Expression of the 67KDA laminin receptor on progenitor cells after 
mobilization with granulocyte-colony stimulating factor is involved in their 
adhesion to stromal microenvironment. 
         N Montuori, P Ragno, P Ricci, R Di Micco, L Maddaluno, V  
         Visconte, G Di Iorio, B Serio, B Rotoli, G Rossi, C Selleri. 
         Haematologica,  88 (Suppl n.15), 463, 2003. 
18. Effects of different treatments on bone mineral density in women with 
precocious ovarian failure after allogneic stem cell transplant for 
haematological malignancies.  
 63 
L Tauchmanova, C Selleri, B Serio, F Orio, C. Di Carlo, G Bifulco, G Lombardi, A 
Colao , B Rotoli, C Nappi. 
        Gynecologycal Endocrinolog, 18 (Suppl 1), 255, 2004. 
19. Involvement of the urokinase-type plasminogen activator receptor in 
hematopoietic stem cell mobilization. 
      C Selleri, N Montuori, P Ricci, V Visconte, MV Carriero, N Sidenius,  
      B Serio, F Blasi, G Rossi, P Ragno, B Rotoli. 
      Haematologica,  (Suppl n.6), 28, 2004. 
20. High serum leptin in patients with chronic graft versus host disease after 
hematopoietic stem cell transplantation. 
      B Serio, L Tauchmanovà, G Matarese, P Ricci, C Carella, G De  
        Rosa, G Cerciello, G Lombardi, A Colao, B Rotoli, C Selleri.  
        Haematologica,  (Suppl n.6), 151, 2004. 
21. Role of the urokinase-type plasminogen activator receptor in  
hematopoietic stem cell mobilization. 
      C Selleri, N Montuori, P Ricci, V Visconte, MV Carriero, N  
       Sidenius, B Serio, F Blasi, B Rotoli, G Rossi, P Ragno.  
       Bone Marrow Transplantation, 35 (suppl 2), 113, 2005.  
22. Involvement of the 67kDa laminin receptor in hematopoietic stem cell 
mobilization and homing. 
      C Selleri, N Montuori, P Ricci, V Visconte, MV Carriero, N Sidenius,  
      B Serio, F Blasi, B Rotoli, G Rossi, P Ragno. 
      Bone Marrow Transplantation, 35 (suppl 2), 116, 2005.  
23. Short-term zoledronic acid treatment increases bone mineral density and 
marrow clonogenic fibroblast progenitors after allogeneic stem cell 
transplantation. 
      B Serio, L Tauchmanovà, P Ricci, G Cerciello, I Imperatore, A  
      Risitano, G De Simone, G Lombardi, A Colao, B Rotoli, C Selleri. 
      Bone Marrow Transplantation, 35 (suppl 2), 189, 2005.  
 
 
Abstract in national and international meeting 
 
24. Bone status as detected by phalangeal quantitative ultrasonometry and 
DEXA in patients after allogeneic stem cell transplantation for 
haematological malignancies. 
      L Tauchmanova, C Selleri, B Serio, G De Rosa, A Del Puente, S  
      Padella, A Carpinelli, F Orio Jr, G Lombardi, B Rotoli, A Colao. 
      3nd International Congress on Glucocorticoid Induced Osteoporosis.  
      Torino, 21, 2003. poster 
25. Avascular necrosis in long-term survivors after allogeneic or autologous 
stem cell transplantation. 
        L Tauchmanova, B Serio, F Fazioli, C Mainolfi, A Rossi, G  
        Lombardi, B Rotoli, C Selleri, A. Colao.  
        6th European Congress of Endocrinology. Lyon, 0503, 2003. poster 
26. Short-term zoledronic acid treatment increases bone mineral density and 
osteogenic progenitors after allogeneic stem cell transplantation for 
haematological malignancies. 
      L Tauchmanova, C Selleri, P Ricci, B Serio, F Orio, T Cascella, C  
      Di Somma, G Lombardi, B Rotoli, A Colao. 
 64 
     86th Meeting of the American Endocrine  Society. New Orleans, 85, 
      2004. poster 
27.   Effects of leptin and IGF-1on bone mineral density in long-term  
        survivors after allogeneic stem cell transplantation for 
        hematological diseases.  
 L Tauchmanova, C Selleri, C Carella, G. Maziotti, B Serio, F Orio, G Lombardi, B 
Rotoli, A Colao.  
11th Meeting of the European Neuroendocrine Association. Naples, 21, 2004. 
poster 
28.  Analysis of Immunogenetic Factors in Paroxysmal Nocturnal 
       Hemoglobinuria Reveal Increased Frequency of IL-10 Low  
       Secretor Genotype and Correlates with Induced IL-10 
       production.      
    G Ramsingh, Z Nearman, Hung , B Serio, A Risitano, J Maciejewski 
       The American Society of Hematology 48th Annual Meeting, 
       Orlando, 2006. poster 
   29. Hemochromatois-Associated Gene Mutations in Patients  
         with Myelodysplastic Syndromes with Refractory Anemia  
         and Ringed Sideroblasts.  
          Z Nearman, B Serio, H Szpurka, I Warshawsky, A Lichtin, M  
          Sekeres,JMaciejewski  
       The American Society of Hematology 48th Annual Meeting,  
          Orlando, 2006. poster 
 30. Double Negative T Cells Influence TCR VB Variablity to  
       Induce Allotolerance.      
        Z McIver, B Serio, M Wlodarski, J Powers, C O'Keefe, T Jin, R      
        Sobecks, B Bolwell, J Maciejewski .  
        The American Society of Hematology 48th Annual Meeting,  
        Orlando, 2006. Oral comunication 
 31. Impact of genetic pholymorphisms on immune response and 
       clinical features in MDS 
       B Serio, Jankowska A, G Ramsingh, Z Nearman, H Szpurka, R  
       Tiu, C O’Keefe, M Sekere, J Maciejewski.  
       The American Society of Hematology 48th Annual Meeting,  
       Orlando, 2006. poster 
32.  Analysis of Immunogenetic Factors in Myelodysplastic 
       Syndromes (MDS) Reveals Potential Pathogenic Role  
       Cytokine Genotypes such as TGF-$. 
       B Serio, R Tiu, A Jankowska, Z Nearman, C O'Keefe, M A  
       Sekeres and J Maciejewski . 
       The American Society of Hematology 49th Annual Meeting,  
        Atlanta,2007.poster 
33.  Decreased Numbers of Tregs in Aplastic Anemia is Detected  
       by Immunohistochemistry and Flow Cytometry.  
        B Serio, Z Peerwani, R Tiu, J Powers, E Hsi, and J Maciejewski.   
       The American Society of Hematology 49th Annual Meeting,  
       Atlanta, 2007. poster 
34. Immunogenetic Analysis Reveals the Association of INF-!   
      (+874 A/T) Hypersecretor Genotype in AA and a Low  
      Frequency of KIR-2DL3/C1 Mismatch in Responders to  
 65 
      Immunosuppression. 
      B Serio, G Ramsingh, R Tiu, A M Risitano, M A Sekeres, and  
      J Maciejewski.  
     The American Society of Hematology 49th Annual Meeting,  
     Atlanta, 2007. poster 
35. Non Synonymous SNP-Array-Based Disease Association 
      Analysis in Aplastic Anemia and Paroxysmal Nocturnal  
      Hemoglobinuria.  
      B Serio, A D Viny, R Tiu, B Przychodzen, A Lichtin, C O'Keefe,  
      J Maciejewski.  
      The American Society of Hematology 49th Annual Meeting,  
      Atlanta, 2007. poster 
36. Impact of Cytokine Gene Polymorphisms in Aplastic Anemia 
      (AA) 
      B Serio, AM Risitano, G Ramsingh, R Tiu, A Viny, B  Rotoli,  C   
      Selleri and J Maciejewski.  
      41th Italian Society of Hematology, Bologna, Italy, 2007. Oral 
     comunication 
37. Impact of Cytokine Gene Polymorphisms in Myelodysplastic 
      Syndromes (MDS) 
      B Serio, AM Risitano, A Jankowska, Z Nearman, C O’Keefe, B 
      Rotoli, C  Selleri and J Maciejewski. 
      41th Italian Society of Hematology, Bologna, Italy, 2007. Oral  
     comunication 
38. Circulating T regulatory cells (treg) are decreased in patients  
      with Aplastic Anemia (AA)            
      B Serio, AM Risitano, J Powers, Z McIver, B Rotoli, C Selleri and J  
      J Maciejewski. 
     41th Italian Society of Hematology, Bologna, Italy, 2007. Oral   
     comunication 
39. Double negative tregs are reduced in allo-transplanted  
      patients developing graft-versus-host disease. 
      B Serio, Z McIver, A M Risitano, C Selleri and J Maciejeski.  
     34th Annual Meeting of the European Group for Blood and Marrow  
     Transplantation , Florence, 2008. Oral comunication 
40. Permissive Conditions for Evolution of PNH clones are 
      Characterized by Overproduction of IFN-g by Clonal CD4 and 
      CD8 T cells, Fas-L by CTLs, and Promoted by Immunogenetic  
      Background.   
      M Clemente, H Cazzolli, A Jankowska, B Serio, S Nyland, M  
      Wlodarski, PK Burnette, R Paquette, J Maciejewski 
     The American Society of Hematology 50th Annual Meeting,  
      San Francisco, 2008. poster 
 
 
 
 66 
APPENDICE 
Elenco pubblicazioni allegate 
 
1) “Double-negative regulatory T cells induce allotolerance when expanded after allogeneic 
haematopoietic stem cell transplantation”. 
McIver Z, Serio B, Dunbar A, O'Keefe CL, Powers J, Wlodarski M, Jin T, Sobecks R, Bolwell B, 
Maciejewski JP. 
Br J Haematol. 2008 Apr;141(2):170-8. Epub 2008 Mar 3. 
 
2) “Hemochromatosis-associated gene mutations in patients with myelodysplastic 
syndromes with refractory anemia with ringed sideroblasts”. 
Nearman ZP, Szpurka H, Serio B, Warshawksy I, Theil K, Lichtin A, Sekeres MA, Maciejewski JP. 
Am J Hematol. 2007 Dec;82(12):1076-9. 
 
3) “High serum leptin in patients with chronic graft-versus-host disease after hematopoietic 
stem cell transplantation”. 
Tauchmanovà L, Matarese G, Carella C, De Rosa G, Serio B, Ricci P, Lombardi G, Rotoli B, Colao 
A, Selleri C. 
Transplantation. 2004 Nov 15;78(9):1376-83 
 
4) “Short-term zoledronic acid treatment increases bone mineral density and marrow 
clonogenic fibroblast progenitors after allogeneic stem cell transplantation”. 
Tauchmanovà L, Ricci P, Serio B, Lombardi G, Colao A, Rotoli B, Selleri C. 
J Clin Endocrinol Metab. 2005 Feb;90(2):627-34. Epub 2004 Nov 16. 
 
5) “Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem 
cell mobilization”. 
Selleri C, Montuori N, Ricci P, Visconte V, Carriero MV, Sidenius N, Serio B, Blasi F, Rotoli B, Rossi 
G, Ragno P. 
Blood. 2005 Mar 1;105(5):2198-205. Epub 2004 Oct 19.  
 
6) “Late relapse of acute promyelocytic leukemia treated with all- trans retinoic acid and 
chemotherapy: report of two cases” 
Ferrara F, Selleri C, Mele G, Serio B, Palmieri S, Pocali B, Pane F, Rotoli B. 
Ann Hematol. 2004 Jul;83(7):484-6. Epub 2004 Jan 17. 
 
 
 
7) “Avascular necrosis in long-term survivors after allogeneic or autologous stem cell 
transplantation: a single center experience and a review”. 
Tauchmanovà L, De Rosa G, Serio B, Fazioli F, Mainolfi C, Lombardi G, Colao A, Salvatore M, 
Rotoli B, Selleri C. 
Cancer. 2003 May 15;97(10):2453-61. 
 
 
8) “Involvement of nitric oxide in farnesyltransferase inhibitor-mediated apoptosis in chronic 
myeloid leukemia cells”. 
Selleri C, Maciejewski JP, Montuori N, Ricci P, Visconte V, Serio B, Luciano L, Rotoli B. 
Blood. 2003 Aug 15;102(4):1490-8. Epub 2003 Apr 24. 
 
 
9) “Long-lasting bone damage detected by dual-energy x-ray absorptiometry, phalangeal 
osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell 
transplantation”. 
Tauchmanovà L, Serio B, Del Puente A, Risitano AM, Esposito A, De Rosa G, Lombardi G, Colao A, 
Rotoli B, Selleri C. 
Journal of Clinical Endocrinology § Metabolism 87, 5058-5065, 2002. 
 
 
